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Summary 
 
Hepatitis B virus (HBV) immunisation protocols in much of Africa are based on data from the 
pre-human immunodeficiency virus (pre-HIV) era that indicated that HBV transmission 
occurs predominantly horizontally between siblings and play-mates rather than vertically 
from mother to child. The immunosuppression associated with HIV infection however may 
release HBV from immune control resulting in higher HBV viral loads, which may increase 
the risk of perinatal mother to child transmission of HBV. The aim of this study was to 
determine the prevalence and characteristics of chronic HBV infection in HIV-infected 
pregnant women compared to HIV-uninfected pregnant women in the Western Cape province 
of South Africa.  
Ethical approval was obtained to conduct a retrospective, matched case-control, unlinked 
anonymous study using residual plasma samples from the 9355 pregnant women included in 
the Western Cape‟s 2008 National HIV and Syphilis Antenatal Survey. Samples were tested 
for HBsAg on the AxSYM (Abbott, Chicago, IL) and confirmed by neutralization. Confirmed 
HBsAg-positive samples were tested for HBeAg, anti-HBe and anti-HD (Diasorin, Saluggia, 
Italy) and had HBV viral load and genotyping done. In addition, HBsAg-negative samples 
were tested for anti-HBc. 
Samples from 1549 HIV-infected pregnant women were included and matched to the same 
number of samples from age- and race-matched HIV-uninfected women. Median age of 26 
years, parity and education were similar in the two groups. The prevalence of HBsAg was 
3.4% for the HIV-infected group and 2.9% for the HIV-uninfected group. HBV DNA loads of 
greater than 10
4 
IU/ml were detected in 32.1% of HBsAg-positive, HIV/HBV co-infected 
women, and in 14.3% HBsAg positive, HBV mono-infected women. Among the HIV-
infected group 18.9% of HBsAg-positive were HBeAg positive, with a median viral load of 
7.93 log10 IU/ml; whilst 15.5% HIV-uninfected women were positive for HBeAg with a 
median viral load of 6.07 log10 IU/ml. Genotype A was seen in 92.6% of the isolates while 
7.4% of the isolates were genotype D. Serum total anti-HBc antibodies that are a marker of 
past infection were detected in 42.2% of HIV-infected and in 24.1% of HIV-uninfected 
women that were negative for HBsAg. No positive sample for anti-HD was seen among all 
HBsAg-positive samples. This data indicates that there is increased exposure to HBV in HIV-
infected pregnant women than in HIV-uninfected women and that a greater proportion of 
HIV-infected pregnant women compared to HBV mono-infected pregnant women may be at 
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increased risk of transmitting HBV to their infants. Further studies are needed to determine 
the rate of vertical transmission of HBV in the HIV era.  
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Opsomming 
 
Hepatitis B virus (HBV) immunisasie protokolle vir meeste dele van Afrika is gebaseer op 
data versamel in die era voor MIV. Die data dui aan dat HBV oordrag hoofsaaklik deur 
horisontale transmissie tussen broers, susters en speelmaats eerder as vertikale transmissie van 
moeder na kind plaasvind. Die onderdrukking van die immuunstelsel as gevolg van MIV 
infeksie kan egter lei tot „n verhoogde risiko van perinatale HBV oordrag van moeder na kind. 
Die doel van hierdie studie was om die voorkoms en karakter van chroniese HBV infeksie in 
MIV-positiewe swanger vroue te vergelyk met die van MIV-negatiewe swanger vroue.   
Etiese goedkeuring is verkry om „n retrospektiewe, deursnee-, ongekoppelde anonieme studie 
uit te voer wat gebruik maak van oorblywende plasma monsters van 9355 swanger vroue wat 
ingesluit is in die Wes-Kaap 2008 Nasionale MIV en Sifilis Voorgeboortelike Opname. Die 
monsters was getoets vir HBsAg antiliggame (AxSYM, Abbott, Chicago, IL) en bevestig deur 
neutralisasie toetse. Positiewe monsters was getoets vir HBeAg en anti-HBe (Diasorin, 
Saluggia, Italië). HBV viruslading en genotipering was ook op HBsAg positiewe monsters 
gedoen. Die HBsAg negatiewe monsters was getoets vir die teenwoordigheid van anti-HBc.  
Monsters van 1549 MIV-positiewe swanger vroue was ingesluit in die studie. Dieselfde aantal 
monsters van MIV-negatiewe vroue, met ooreenstemende ouderdom en etnisiteit, was 
ingesluit as kontroles. Die gemiddelde ouderdom van albei groepe was 26 jaar. Pariteit en 
opvoeding was dieselfde in albei groepe. Die voorkomssyfer van HbsAg was 3.4% in die 
MIV-positiewe groep en 2.8% in die MIV-negatiewe groep. HBV DNS ladings van meer as 
10
4 
IU/ml was waargeneem in 32.1% van die MIV-mede-geinfekteerde vroue en in 14.3% van 
die MIV-negatiewe groep. In die MIV-positiewe groep was 18.9% vroue HBeAg positief, met 
„n gemiddelde virale lading van 7.93 log10 IU/ml, terwyl 15.5% MIV-negatiewe vroue positief 
was vir HBeAg met „n gemiddelde virale lading van 6.07 log10 IU/ml. In ons studie was 
92.6% van die monsters genotipe A en 7.4% genotipe D. Toatale anti-HBc antiliggame, „n 
merker van vorige infeksie, was gevind in 42.2% van MIV-mede-geïnfekteerde vroue en 
24.1% van MIV-negatiewe vroue wat negatief was vir HBsAg antiliggame. 
Data van ons studie dui op „n verhoogde risiko vir vertikale HBV transmissie van MIV-
positiewe moeders na hul babas. Verdere studies word benodig om vas te stel of vertikale 
transmissie van HBV van MIV-positiewe vroue na hul babas plaasvind. 
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“There are two possible outcomes: if the result confirms the hypothesis, then you've made a 
measurement. If the result is contrary to the hypothesis, then you've made a discovery.” 
Enrico Fermi 
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CHAPTER ONE 
 
1. Introduction 
1.1. Global HBV epidemiology 
Infection with HBV poses a major public health concern and is rated among the ten leading 
causes of death worldwide despite availability of a safe and effective vaccine (Mphahlele and 
Francois, 2008; World Health Organization [WHO], 2008; Lavanchy, 2004; Kiire, 1996). It is 
estimated that two billion people worldwide have been infected with HBV, with more than 
350 million becoming chronically infected (WHO, 2008). It is also estimated that globally, 
about 10-30 million new infections occur annually and that over 600 000 people die each year 
from diseases related to HBV infection (WHO, 2008; Cooley and Sasadeusz, 2003). Chronic 
HBV (CHB) infection is particularly common in Asia and Africa where the virus is usually 
acquired either perinatally or in early childhood respectively (Hoffmann and Thio, 2007). 
CHB may be defined as continuous detection of HBV surface antigen (HBsAg) in a patient‟s 
sample for over six months (Soriano et al., 2010; Hoffmann and Thio, 2007; Shepard et al., 
2006).  
 
1.2. HBV epidemiology in Africa 
Most African countries are classified as areas of high HBV endemicity. High endemicity for 
HBV is defined as CHB prevalence of ≥8%, intermediate endemicity is 2-7% and low 
endemicity refers to a prevalence of less than 2% (Heathcote, 2008; Hou et al., 2005). 
However, even within highly-endemic countries there is some variation in the distribution of 
HBV, with pockets of low and intermediate endemicity being seen.  
The global differences in prevalence rates of CHB have been associated with differences in 
the age at acquisition of the virus (Heathcote, 2008; Hou et al., 2005). There is an inverse 
relationship between the risk of becoming a chronic HBV carrier and the age at acquisition of 
infection with about 90% of infants who get infected within the first year of birth progressing 
to chronic infection (Tran, 2009; WHO, 2008). This is in contrast to more than 90% of 
healthy adults that get infected and recover (Tran, 2009; WHO, 2008). Statistics estimate that 
about 18% of the global population of chronic carriers of HBV reside in Africa with sub-
Saharan Africa being home to a greater number of this population (Kramvis and Kew, 2007a).   
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Figure 1.1 Map of CHB prevalence according to geographical distribution. [Source: CDC, 2006] 
 
It is estimated that in South Africa alone, there are between three to four million black people 
that suffer from CHB (Kew, 2008; Kew, 1996). Prevalence of HBV among pregnant women 
varies in different parts of the world with rates between 0.1% - 20% (Sinha and Kumar, 
2010). In sub-Saharan Africa, there is a trend of higher prevalence rates of CHB in males than 
in females (Kew, 2008). In addition to infection by HBV, sub-Saharan Africa is also the 
region worst affected by the HIV pandemic being home to about 70% of the global population 
of 33 million people who are HIV-infected (UNAIDS, 2009).  
HBV and HIV share transmission routes and it has been estimated that 80% of HIV-infected 
persons are exposed to HBV and that 4%-16% of the same population are chronically infected 
with HBV (Trevino et al., 2009; Mphahlele et al., 2006; Thimme et al., 2005). Co-infection 
with HIV alters the natural history of HBV infections, delaying the seroconversion to anti-
HBe, causing higher replication rate and reactivation of infection despite the presence of anti-
HBs (Hoffmann and Thio, 2007; Cooley and Sasadeusz, 2003; Puoti et al., 2002). Results 
from a Zambian study showed that pregnant women with dual HIV and HBV infections were 
twice as likely to have detectable HBeAg in their sera compared to those who were infected 
with HBV only (Oshitani et al., 1996). A study from Côte d‟Ivoire found that the detection of 
plasma HBV DNA was more frequent in the co-infected HBV carrier than in HBV mono-
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infected carriers (Rouet et al., 2004). Also, a study from Burkina Faso which is a country of 
moderate HIV prevalence revealed that HIV infection is a factor that is significantly 
associated with increased mother-to-child transmission of HBV (Sangare et al., 2009). Earlier 
data indicates that occult HBV infection may also be more common in HIV-infected patients 
(Kew, 1996). The findings by Kew are supported by a more recent study in SA which found 
that occult HBV infection is more prevalent in HIV-infected patients than in HIV-uninfected 
individuals although the study also reported a lower carriage of HBsAg in HIV seropositive 
patients (Mphahlele et al., 2006). The same study however found a statistically significant 
higher carriage of HBsAg in the HIV seronegative patients than in HIV-infected patients. 
Burnett et al. reported HBsAg prevalence of 7.4% in HIV-infected and 8.2% in HIV-
uninfected pregnant women in South Africa (Burnett et al., 2007). The study by Burnett et al. 
was performed on samples from the national HIV antenatal surveys covering the period 1999-
2001 collected from women who attended antenatal clinics in the Limpopo Province and 
North West Province of South Africa. However, a study by Firnhaber et al. in the Gauteng 
Province of South Africa reported an increased prevalence of HBV carriage in HIV-infected 
patients than in HIV-uninfected individuals (Firnhaber et al., 2009). These observed 
differences between HIV patients and pregnant women is likely to be explained by the 
differences in their immune status. Firnhaber et al. utilised samples from patients who were 
just about to start ART and had CD4 cell counts below 200 cells/ml. Also, the cohort 
comprised of both male and female gender. Perinatal transmission of occult HBV has not 
been well described although one study reported of a mother who had occult infection and 
transmitted the virus to her daughter (Saito et al., 1999). However, high HBV DNA levels as 
much as 10
8
 IU/ml that were observed in some HIV-infected patients with occult infection 
may facilitate vertical transmission (Lukhwareni et al., 2009; Mphahlele et al., 2006). In 
addition, vertical transmission of occult infection with woodchuck hepatitis virus (WHV) has 
been observed in woodchucks which are considered as the natural model of human HBV 
infection (Mulrooney-Cousins and Michalak, 2007). Taken together these findings suggest 
that the epidemiology of HBV in the antenatal setting may be changing, although the situation 
in South Africa is largely unknown.  
 
1.3. Rationale for the study 
As the immune suppression associated with progression of HIV becomes evident, it is 
apparent that there is increased HBV replication and infectivity that have been reported 
elsewhere. Previous findings of higher rates of HBV DNA and occult HBV infection that 
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have been seen on hospitalised or AIDS patients cannot be extrapolated onto HIV-infected 
pregnant women (Lukhwareni et al., 2009; Mphahlele et al., 2006). HIV-infected pregnant 
women are likely to be healthier than AIDS and hospitalised patients. Previous studies done 
in other provinces of South Africa using serology and HBV DNA testing have suggested that 
vertical transmission of HBV from HIV-infected mothers may not be a problem (Burnett et 
al., 2007). Thus this study is needed because only one province in South Africa has been 
studied, and we need to know what the situation is in other provinces as well. It is agreed that 
prevalence of HBV within a particular country may not be uniform across all region. 
Importantly, there are no data on HBV viral loads in pregnant women in South Africa, and 
this data is needed to see if HBV viral loads in the co-infected are higher than in the mono-
infected.  
 
1.4. Significance of study 
The data from this study is important for determining evidence of exacerbation of HBV 
infection in HIV/HBV co-infected pregnant women. When combined together with data on 
the current rates of perinatal HBV infection, the study is useful for determining whether there 
may be a need to alter immunisation schedules for HBV to take account of HIV/HBV co-
infection in South Africa.  
 
1.5. Aims and Objectives 
This study was conducted to determine the prevalence and characteristics of HBV infection 
among HIV-uninfected and HIV-infected pregnant women in the Western Cape province of 
South Africa.  
The objectives of the study were- (i) to measure and compare the prevalence of HBsAg, 
HBeAg, anti-HBe, anti-HBc, anti-HD and HBV DNA in HIV-infected and HIV-uninfected 
pregnant women, (ii) to measure and compare HBV viral loads in HIV-infected and HIV-
uninfected pregnant women, (iii) to determine HBV genotypes in HIV-infected and HIV-
uninfected pregnant women, and (iv) to identify mutations in the overlapping polymerase and 
surface antigen regions of the HBV genome in HIV-infected and HIV-uninfected pregnant 
women. 
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CHAPTER TWO 
 
2. Literature review 
2.1. HBV virology 
HBV has a deoxyribonucleic acid (DNA) genome and belongs to the Hepadnaviridae family 
under the subgroup human hepatitis virus (Ganem and Prince, 2004; Cooley and Sasadeusz, 
2003). HBV exhibits tropism for hepatic cells although small amounts have also been found 
in other cells from the kidneys, pancreas and mononuclear cells (Ganem and Prince, 2004). 
The virus has a 3.2kb genome composed of circular DNA that is partially double-stranded 
because of an incomplete positive sense strand (Howard, 1986).  
The complete and infectious HBV virion, which is also known as the Dane particle, has a 42 
nm diameter and is composed of an icosahedral nucleocapsid core of 27 nm diameter that is 
surrounded by a lipoprotein envelope (Francois et al., 2001; Howard, 1986). The nucleocapsid 
core is made up of viral DNA bound with the polymerase enzyme and surrounded by the 
HBV core antigen. The lipid component of the lipoprotein envelope is derived from the host 
internal membranes during budding while the glycoprotein is a product of the preS-S gene of 
the virus (Harrison et al., 2008b). The lipoprotein envelope containing surface antigen is 
approximately 4 nm thick (Chen et al., 2008). A schematic diagram of the HBV virion is 
shown in Figure 2.1. 
 
Figure 2.1 Schematic diagram of a complete HBV virion. [Source: Chen et al., 2008] 
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The HBV genome contains four open reading frames (ORFs) that overlap each other in a 
frame-shifted manner to produce seven identified proteins. These four open reading frames 
are C, P, S and X (Lüsebrink, 2009). ORF-C (core/precore) codes for the HBV core protein 
(HBc) and the HBV e antigen (HBeAg). The core protein is vital for viral assembly and 
makes the nucleocapsid that encapsulates the viral DNA and the polymerase while HBeAg 
has no role in viral assembly but is known to induce immunotolerance. Although HBeAg does 
not have a role in viral assembly and is secreted protein, its detection in blood serves to show 
active replication of HBV and is used as a marker of high infectivity (Harrison et al., 2008). 
ORF-P codes for the polymerase enzyme that is involved in replication and also has 
transcriptase as well as RNAse H activity. ORF-S (preS-S) contains genetic information for 
the three polypeptides of the surface antigen (preS1, preS2 and S). Surface antigen proteins of 
different lengths are produced depending on which translation site has been read for initiation 
within the gene but all share the same C-terminus (Lüsebrink, 2009; Harrison et al., 2008b; 
Ganem and Prince, 2004). Antibodies against the surface antigen (anti-HBs) confer immunity 
to HBV (Harrison et al., 2008b). ORF-X codes for a transactivator of viral transcription 
(Lüsebrink, 2009; Pawlotsky, 2006). The X protein may modulate expression of both viral 
and host genes and is vital for viral replication and transmission (Ganem and Prince, 2004). 
Figure 2.2 depicts the genome organization of HBV. 
Besides the Dane particles, HBV also occurs in two other distinct physical forms which are; 
(i) small, spherical, non-infectious particles, containing HBsAg, that on average measure 22 
nm in diameter and (ii) tubular, filamentous forms of various lengths, but with same diameter 
as the spherical forms and also contain HBsAg (Lüsebrink, 2009; Bruss, 2007). The spherical 
and filamentous forms are however non-infectious as they are devoid of nucleic acids but are 
found in excess of the infectious particles by factors of up to 10 000 fold (Bruss, 2007). These 
excess subviral particles are thought to subvert the immunological response to surface 
proteins by mopping up low level anti-HBs thereby allowing infectious particles to escape 
from the immune system (Harrison et al., 2008b; Maruyama et al., 1993). The subviral or 
HBsAg particles share same antigens as the complete virions, although the protein 
composition is different (Bruss, 2007). Complete virions have the highest content of large 
HBsAg (L) protein, the filamentous forms have lesser and the spherical subviral particles 
have the least relative amount of L within their structure. 
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Figure 2.2 Genome organisation of HBV and its transcripts. [Source: Lüsebrink et al, 2009] 
 
2.1. HBV replication 
The receptors required for hepatocyte infection by HBV are as yet unknown although it is 
believed that first contact involves a domain located near to the N-terminus of L (absent in M 
or S), and other interactions involving S may also be important (Harrison et al., 2008b). It is 
thought that when pre-S1 is expressed, L is translocated into the lumen of the endoplasmic 
reticulum where it may then be exposed on the exterior of the viral particle and then presents 
as the receptor-binding domain (Harrison et al., 2008b). Virus entry is posited to be through 
the endosomal route and results in the delivery of the genome to the nucleus (Harrison et al., 
2008b). When the genome has been delivered to the nucleus, there is repair of the incomplete 
positive strand and subsequent formation of covalently closed circular DNA (cccDNA) 
(Ganem and Prince, 2004). Repair of the incomplete strand is thought to be due to a host 
enzyme (Harrison et al., 2008b). The cccDNA serves as the transcriptional template for host 
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RNA polymerase II which leads formation of 3.5-kb pregenomic and precore (pre-C) RNAs 
(Quasdorff and Protzer, 2010). Core and polymerase/reverse transcriptase proteins are 
transcribed from pregenomic RNA (Quasdorff and Protzer, 2010). HBeAg is translated from 
pre-C mRNA (Quasdorff and Protzer, 2010). One molecule of genomic ribonucleic acid 
(RNA) is enclosed in the viral capsid as the nucleocapsid is constructed in the cytoplasm 
(Ganem and Prince, 2004). Once encapsidation has occurred, reverse transcription of the 
genomic RNA to DNA by the viral polymerase begins (Ganem and Prince, 2004). Use of a 
reverse transcriptor is a feature that HBV shares with retroviruses although the former is a 
DNA virus. A total of 240 subunits of core protein are combined to make the viral capsid 
which in some way directs the arrangement of the envelope proteins (Quasdorff and Protzer, 
2010). 
The viral envelope, which is composed of a lipid bilayer that is densely packed with the large 
(L), middle (M) and predominantly the small (S) envelope proteins, is gained when the 
capsids bud into the intracellular membranes (endoplasmic reticulum) into which the surface 
proteins (HBsAg) are embedded (Harrison et al., 2008a; Ganem and Prince, 2004). The 
complete viral particles are then transported out the cell. However, some capsids that contain 
the normal HBV genome shuttle back to the nucleus. Once in the nucleus, the HBV DNA is 
again repaired to form cccDNA. The cccDNA maintains a pool of HBV mRNAs inside the 
nucleus of host cells (Ganem and Prince, 2004). Figure 2.3 summarizes the process of HBV 
replication. 
 
2.2. Molecular epidemiology of HBV 
HBV is widely classified into eight genotypes (A-H) which have distinctive geographical 
distribution (Audsley et al., 2010; Yu et al., 2010; Tatematsu et al., 2009). However, two 
additional genotypes I and J, have recently been described in Asian patients (Yu et al., 2010; 
Olinger et al., 2008). Genotype I is described as having evolved from recombination events 
(Yu et al., 2010; Olinger et al., 2008). It may therefore be questionable if I and J are true 
genotypes. HBV genotype classification is based on sequence heterogeneity either in the 
entire genome length or in the S gene (Kramvis et al., 2005; Kramvis and Kew, 2005). HBV 
genotypes are defined by divergence in the entire HBV genomic sequence of more than 8% or 
more than 4% at the level of the S gene (Hou et al., 2005; Kramvis et al., 2005; Kao and 
Chen, 2002). Some researchers have advocated using the entire genome sequence to allow 
detection of recombination of different genotypes that may arise as a result of co-infection by 
more than one genotype (Hou et al., 2005; Kramvis et al., 2005).  
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Figure 2.3 Illustration of the replication process of HBV. [Source: Ganem and Prince, 2004] 
 
HBV genotype A is endemic to Europe, North America and Africa, genotypes B and C are 
predominant in Asian populations, whereas D has a worldwide distribution but is more 
common in the Mediterranean area, genotype E is restricted to Africans, F is found in the 
aboriginal populations of South America, H is confined to the indigenous populations of 
Central America and G has been isolated in carriers in developed countries (Hou et al., 2005; 
Kramvis et al., 2005; Kao and Chen, 2002). Knowledge of the various genotypes is important 
because of the clinical and epidemiological implications of individual genotypes (Kramvis 
and Kew, 2007a; Kramvis et al., 2005). Different genotypes have also been linked to perinatal 
transmission of HBV (Sinha and Kumar, 2010: Hou et al., 2005; Kao and Chen, 2002). 
Genotypes B and C are prevalent in Asian countries that are mostly highly endemic and where 
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mother-to-child transmission is particularly responsible for the spread of the virus. It is 
thought that vertical transmission may be responsible for conservation of these genotypes in 
the population (Hou et al., 2005). In contrast, the other genotypes (that is excluding B and C) 
are prevalent in areas where horizontal transmission is the main route of infection because 
these are associated with early seroconversion to anti-HBe (Kao and Chen, 2002).  
 
2.3. Natural history and pathogenesis of chronic HBV 
The natural history of chronic HBV infection (CHB) falls into four phases (Heathcote, 2008; 
Hoffmann and Thio, 2007). The phases are- immunotolerant, immunoactive, inactive carrier, 
and reactivation (Heathcote, 2008; Hoffmann and Thio, 2007). An increasingly-recognized 
category of occult HBV infection is also acknowledged and increasingly gaining importance 
(Hoffmann and Thio, 2007). The immunotolerant phase is characterized by active viral 
replication, punctuated by high plasma HBV DNA, presence of HBeAg, normal alanine 
aminotransferase (ALT), and little histologic activity. The immunotolerant phase is observed 
almost exclusively in persons infected neonatally or in early childhood and may last for 
several decades (Heathcote, 2008; Hoffmann and Thio, 2007). The immunotolerant phase is 
usually absent in persons who acquire HBV in adulthood (Hoffmann and Thio, 2007). The 
immune clearance or “immunoactive” period follows as the immune system attempts to 
remove the virus by attacking infected host liver cells (Heathcote, 2008; Hoffmann and Thio, 
2007). HBV replication gradually declines, although HBeAg is still secreted during immune 
clearance (Heathcote, 2008). Some individuals in the immunoactive phase may develop 
mutation(s) in either the pre-core or core region causing reduced or non-expression of HBeAg 
(Hoffmann and Thio, 2007). The mutant virus in such individuals remains competent to 
replicate and may cause high HBV DNA loads hence infectivity even in the absence of 
HBeAg (Hoffmann and Thio, 2007). The third phase is the inactive carrier state where 
antibodies to HBeAg (anti-HBe) are detected, HBV DNA is not found in blood, and this 
phase may continue indefinitely (Heathcote, 2008; Hoffmann and Thio, 2007). Serum ALT 
normalizes and liver disease becomes inactive and some degree of histologic regression may 
take place in the inactive carrier state (Heathcote, 2008). The reactivation phase occurs in 
persons who, despite testing negative for HBeAg, have elevated HBV DNA levels and 
ongoing intermittent hepatitis (Heathcote, 2008). 
Intracellular HBV is not considered to be directly cytopathogenic to host cells in 
immunocompetent persons and this is a good strategy for its own survival (Lüsebrink, 2009; 
Grob, 1998). This notion is supported by the fact that many HBV carriers do not show 
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symptoms and there is little liver injury, regardless of continued replication of the virus inside 
the hepatocytes (Pungpapong et al., 2007).  However, presentation of processed HBV 
peptides to cytotoxic CD8+ lymphocytes through human leukocyte antigen (HLA) class 1 
molecules causes immune-mediated deletion of infected hepatocytes (Grob, 1998). Liver 
pathology arises from these efforts of the immune system to clear the virus and this may in 
turn cause acute hepatitis (Heathcote, 2008; Ganem and Prince, 2004; Grob, 1998). However, 
direct cytopathogenecity of HBV has been described in AIDS patients in a condition called 
fibrosing cholestatic hepatitis (FCH) where prolonged immunosuppression and excessive 
replication are the hallmarks (Kao and Chen, 2002).  
The high rates of chronic carriage in childhood acquired HBV is partly explained by the 
immaturity of the immune systems in children (Pungpapong et al., 2007). An immature 
immune system means that children cannot mount an effective immune response to clear the 
virus. However, the explanation that children have an immature/underdeveloped immune 
system has been partly refuted by researches that have shown that the infants respond well to 
the HBV vaccine. The inability of children to clear HBV stands in contrast to some patients 
that experience fulminant hepatitis for a brief duration because of a strong immune response 
that is mounted against the virus resulting in viral clearance (Pungpapong et al., 2007). 
Fulminant hepatitis results from an unintended attack on hepatocytes as immune cells fight 
against the virus. 
The worst outcomes of CHB include the development of cirrhosis and hepatocellular 
carcinoma. The highest rates of hepatocellular carcinoma (HCC) are observed in regions that 
are highly endemic for HBV, sub-Saharan Africa being one of the three regions of high HCC 
incidence (Kew, 2010). The prevalence of HCC in sub-Saharan Africa is high in males and it 
tends to affect younger ages than is seen in other geographical locations (Kew, 2010).  
 
2.4. HBV transmission 
HBV may be transmitted vertically or horizontally but in all cases, direct/indirect contact with 
infected body fluids is a requirement (Lüsebrink, 2009). The different modes of transmission 
for HBV include; 
 Vertical which refers to transmission from a mother to her infant and this may occur in 
utero, at the time of birth, or after birth. In utero transmission is rare. Vertical 
transmission is high when the mother is HBeAg seropositive. Up to as much as 90% 
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of infants born to HBeAg seropositive mothers may become chronically infected 
compared to only 10-30% of infants that are born to mothers who are only positive for 
HBsAg (Hoffmann and Thio, 2007; Hou et al., 2005). Vertical transmission is thought 
to play a minor in sub-Saharan Africa but predominates in Asia. 
 Horizontal infection in childhood which is defined as transmission that is unrelated to 
known sexual, perinatal or parenteral exposure (Davis et al., 1989). This may be 
facilitated by via minor breaks in the skin or mucous membranes or close bodily 
contact with other children or close family members. Most infections in sub-Sahara 
African children are attributed to horizontally acquired HBV. Horizontal transmission 
may occur through other close community members although intrafamilial spread is 
more common than interfamilial. Horizontal transmission may occur through 
contaminated inanimate objects such as toothbrushes, razors, and even toys because 
HBV can survive for long periods outside the human body (Wasmuth, 2009). Children 
who acquire HBV infection horizontally when they are still under 5-years of age are 
likely to become chronic carriers and are susceptible to adverse long-term effects 
(Davis et al., 1989). 
 Sexual transmission from unprotected intercourse. In the USA, it is estimated that 
about 40% of new HBV infections are attributed to heterosexual transmission while 
25% of new infections occur in men who have sex with men (Wasmuth, 2009). 
 Percutaneous transmission that is associated with intravenous drug use when drug 
users share a contaminated needle/syringe. Statistics from developed countries, such 
as the USA and Europe where intravenous drug use is more common, indicate that 
15% of new infections may be due to percutaneous transmission (Wasmuth, 2009).  
 Transfusion-associated infection that is linked to use of contaminated blood and blood 
products. Mathematical models that have been used in Sub-Saharan Africa estimate 
that transfusions from contaminated blood would potentially be responsible for almost 
29 000 HBV infections if the required 6.65 million units of blood that are required for 
the region‟s population were to be issued (Jayaraman et al., 2010).  
 Nosocomial infections which are hospital-acquired and may occur between patient and 
patient or between patient and health care worker in either direction. It also includes 
needle-stick injuries to healthcare workers from syringes and apparatus that are 
contaminated with HBV. In a recent study in the USA, health-care associated 
transmission accounted for 18.6% of new infections (Daniels et al., 2010). 
Nosocomial infections also occur in the hospital-setting due to unsafe injection 
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practices when the same needle is used on multiple patients without being sterilized 
(Simonsen et al., 1999). 
 Organ transplantations including liver, kidney and cornea transplants (Wasmuth, 
2009). 
 
CHB is common in many countries in Southern Africa and is maintained because of ongoing 
networks of transmissions in infancy (horizontal transmission) (Kramvis and Kew, 2007a; 
Kew, 1996; Kiire, 1996). Perinatal transmission is considered uncommon in sub-Saharan 
Africa because of the low infectivity of mothers. Studies have shown that very few pregnant 
HBsAg carriers in southern Africa carry HBeAg when compared to Asian women and this 
may account for relatively low rates of perinatal infection in sub-Saharan Africa (Burnett et 
al., 2005; Madzime et al., 1999; Kiire, 1996).  
HBeAg is generally accepted as the marker of high infectivity (Gilbert et al., 2002; Francois 
et al., 2001; Kiire, 1996). However, the absence of HBeAg is not synonymous with non-
infectivity as some HBV variants exist which will not shed HBeAg even in the most 
infectious phases. These variants have a mutation in the pre-C region which results in 
introduction of a premature stop codon that prevents further synthesis of HBeAg. Studies 
from African countries have found the prevalence of HBeAg to be <2-24% among HBsAg 
positive pregnant women (Sinha and Kumar, 2010; Kiire, 1996; Guidozzi et al., 1993; 
Prozesky et al., 1983). 
 
2.5. HBV diagnosis 
The diagnosis of HBV infection is made using a combination of serologic, virologic, 
biochemical, and histologic tests. Immunological tests are the primary diagnostic utility for 
HBV (Dény and Zoulim, 2010). The HBsAg test in the mainstay for screening of both acute 
and chronic infection (Gish, 2008) together with detection of antibodies against the 
capsid/core antigen (Dény and Zoulim, 2010). HBsAg is detected early during acute infection, 
on average 6–10 weeks after exposure and several weeks before symptoms are observed 
(Chevaliez and Pawlotsky, 2008). When immunological tests for anti-HBc and HBsAg are 
negative, it is highly unlikely that the patient is infected with HBV. When both HBsAg and 
total anti-HBc are detected in the serum, acute or chronic infection can be differentiated by 
clinical history and anti-HBc IgM detection (Dény and Zoulim, 2010). It is noteworthy that a 
positive result for anti-HBc IgM does not always point to the presence of an acute infection 
and may be due to low levels of IgM arising from reactivation of CHB (Dény and Zoulim, 
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2010). It is advised that a first positive test for HBsAg be confirmed using an HBsAg 
confirmatory assay to exclude false positive results (Chevaliez and Pawlotsky, 2008). 
Detection of HBsAg for more than six months defines a chronic infection. Nevertheless, 
HBsAg may fail to be detected in some patients even though they are infected. Such results 
may be observed when: (i) there is low viral replication in asymptomatic carriers, (ii) the 
carrier harbours HBV mutants whose surface antigen does not bind to antibodies used in 
commercial assays, (iii) when infection clears spontaneously or after successful antiviral 
therapy in chronic HBV-infected patients and, (iv) in HDV/HBV co-infected patients, where 
hepatitis delta virus may prevent HBV replication and expression (Chevaliez and Pawlotsky, 
2008). 
In addition to the primary serologic diagnostic markers, additional markers are employed in 
HBV prognosis. Presence of antibodies to the surface antigen (anti-HBs) normally represents 
immunity to HBV either from vaccination (anti-HBs alone) or from a resolved infection (anti-
HBs together with anti-HBc) (Chevaliez and Pawlotsky, 2008). However, simultaneous 
presence of anti-HBs and HBsAg has been described and is thought to occur in chronic 
carriers who develop immune-escape mutants (Colson et al., 2007).  HBeAg and anti-HBe are 
used to determine the infectivity status of an HBV-infected patient although these may be 
affected by the presence of pre-core mutants which do not result in secretion of HBeAg. In 
addition, HBV DNA detection and quantification are also employed to determine the need for 
treatment and response to therapy as well as exploring viral reactivation (Dény and Zoulim, 
2010). HBV DNA detection has also become a useful marker for detection of occult 
infections where surface antigen is not detected while genotyping is gaining widespread 
importance for predicting HBV disease progression and treatment response (Soriano et al., 
2008). 
 
2.6. HBV treatment 
There is no specific treatment for acute HBV infection and the goal is usually to maintain 
comfort and adequate nutritional balance, including replacement of fluids that are lost from 
vomiting and diarrhoea (WHO, 2008). In contrast, there are currently seven Food and Drug 
Administration Agency (FDA)-approved drugs, including interferon for treating CHB 
(Soriano et al., 2008). The desired targets for treating CHB are prevention of the development 
of progressive disease, particularly cirrhosis and liver failure, as well as hepatocellular 
carcinoma (Dény and Zoulim, 2010; Hoffmann and Thio, 2007; Ganem and Prince, 2004). 
There are two classes of drugs used to treat chronic HBV namely, immunomodulators and 
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antivirals. This classification is rather variable as the immunomodulators also exert direct 
antiviral activity. The immunomodulators widely used are natural interferon-α-2b and 
pegylated interferon-α-2a (Dény and Zoulim, 2010; Chevaliez and Pawlotsky, 2008). The 
FDA-approved antivirals are nucleos(t)ide analogues that target the reverse transcriptase 
activity of the polymerase enzyme in a similar fashion to anti-HIV drugs. The nucleos(t)ide 
analogues include lamivudine (LAM), tenofovir (TDF), entecavir (ETV), telbivudine (LdT) 
and adefovir dipivoxil (ADV) (Dény and Zoulim, 2010). However, the efficacy of antivirals 
in HBV treatment is dampened by the development of drug-resistance mutations within the 
viral genome (Ohkawa et al., 2008). 
 
2.7. HBV vaccination and post-exposure prophylaxis 
HBV used to be frequently transmitted by transfusion during the 1970s before screening of 
donated blood could be performed (Wedermeyer, 2009). With the advent of improved 
diagnostic tests and screening of blood products for transfusion transmissible infections, 
vertical transmission or horizontal transmission and sexual exposure have become the most 
frequent routes of HBV infection (Wedermeyer, 2009; Lavanchy, 2004). To curb increased 
horizontal and vertical transmission, WHO in 1991 recommended general vaccination against 
HBV in all countries (Wedermeyer, 2009; Lavanchy, 2004). The first plasma-derived HBV 
vaccine was approved by the FDA in 1981 followed later by recombinant vaccines produced 
in yeast cells in 1986 (Wedermeyer, 2009; Lavanchy, 2004). The first national universal 
vaccination programme that was introduced in Taiwan in 1984 to vaccinate all infants led to a 
reduction of the overall HBsAg prevalence from 9.8% in 1984 to 1.3% in 1994 among 
children <15 years of age (Wedermeyer, 2009; Lavanchy, 2004). Improved maternal 
screening for HBV carriers also led to a reduction of the HBV carrier population in Taiwan 
(Chen et al., 1996). In addition to vaccination, high-titre hepatitis B immunoglobulin (HBIG) 
is also available for post-exposure prophylaxis of non-immune subjects. Unlike vaccination, 
HBIG only offers short term protection in recipients. HBIG is not widely available in most 
resource-poor countries because of its cost. 
Immunisation protocols in most sub-Saharan African countries are aimed at preventing infant 
infection through horizontal transmissions rather than preventing mother-to-child 
transmission at birth (Hoffmann and Thio, 2007). Thus the first doses of vaccine are given 
later in the postnatal period. The timings for the three doses of vaccine range from 4, 8 and 12 
weeks in Tanzania; 6, 10 and 14 weeks in South Africa and Kenya; to 3, 4 and 9 months in 
Zimbabwe (Mphahlele, 2008). However, these immunisation protocols leave the neonate 
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susceptible to exposure at birth should the mother‟s HBV infection pose a risk of transmission 
at that time. A study conducted in the Eastern Cape province of SA found that neonatal 
transmission was occurring at higher rates than previously reported (Vardas et al., 1999). 
Vardas et al. reported HBsAg prevalence rates of 8.1% and 8.9% in the 0-6- and 7-12-months 
age groups, respectively (Vardas et al., 1999). The HBsAg carriage rates reported by Vardas 
et al. are higher than the rate of 2.5% in newborns to 6 years upon which the current South 
African vaccine schedules were made (Robson and Kirsch, 1991). The current immunisation 
schedules in most sub-Saharan states, including South Africa, are based on studies that were 
conducted before HIV had reached the current pandemic levels. There is little data on how 
HIV co-infection affects transmissibility of HBV from pregnant women (Burnett et al., 2005).  
 
2.8. Effects of HBV/HIV co-infection 
SA has the largest number of HIV infections in the world with nearly 5.3 million people 
living with HIV/AIDS (Joint United Nations Programme on HIV/AIDS [UNAIDS], 2009; 
Mphahlele, 2008; Burnett et al., 2005). The antenatal HIV prevalence rates approach one in 
three in some areas of South Africa. Antiretroviral therapy (ART) for HIV is increasingly 
becoming available in SA and the benefits for those who are HIV-infected are indisputable. 
Most adult and paediatric ART regimens used in South Africa include LAM which also has 
potent HBV antiviral activity (Thimme et al., 2005; Da Silva et al., 2001). LAM is accepted 
as an effective and safe drug for treatment of both HIV and HBV (Clements et al., 2010; 
Sinha and Kumar, 2010; Agarwal and Tiwari, 2009). LAM suppresses HBV and HIV 
replication by inhibition of the RNA-dependent DNA polymerase of both viruses (Coates et 
al., 1992). Unwittingly, use of LAM as monotherapy for HBV as provided for in most of the 
current ART regimens in SA, is associated with the emergence of HBV strains that are LAM-
resistant leading to worsening of liver disease (Papatheodoridis et al., 2005; Liaw et al., 
2004). These drug-resistant viruses carry specific mutations and may be present in more than 
90% of HIV/HBV co-infected patients who have received four years of therapy and their 
development may be potentiated by HIV-related immunosuppression which up regulates 
HBV replication (Matthews et al., 2006; Benhamou et al., 1999).  
With the availability of highly active antiretroviral therapy (HAART) for HIV treatment, the 
incidence of HBV-related liver disease and mortality has also increased (Kew, 2010). It is 
thought that HIV-infected persons who have previously been exposed to HBV are now living 
longer allowing the development of cirrhosis and HCC (Kew, 2010). Even without HIV co-
infection, statistics estimate that 25% of patients with CHB develop HCC (Burnett et al., 
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2005). Data emerging from different studies suggests that HIV hastens the progression of 
chronic HBV to HCC although this is not conclusive. Other studies have suggested that there 
is less liver damage due to the dampened HBV-specific response as a result of HIV-induced 
immunosuppression (Herrero-Martinez, 2001). Also, the use of HAART in HIV/HBV co-
infected patients poses a greater risk of liver disease due to the effects of the immune 
reconstitution syndrome (Burnett et al., 2005). 
The immunosuppression caused by HIV may permit reactivation of latent HBV infections to 
active CHB particularly in patients who have progressed to acquired immunodeficiency 
syndrome (AIDS) (Horvath and Raffanti, 1994; Hudson, 1990). Immunosuppression due to 
HIV may also lead to susceptibility to re-infections in patients previously exposed to HBV 
because such individuals may lose their protective antibodies as they progress to AIDS 
(Horvath and Raffanti, 1994). 
 
2.9. Lamivudine resistance and vaccine escape mutants 
The primary mutation associated with resistance to LAM is the methionine to valine or 
isoleucine change that is seen on amino acid 204 (M204V/I) which occurs in the catalytic 
domain of the HBV RNA-dependant DNA polymerase. On rare occasions a methionine to 
serine change (M204S) may also be seen.  A range of other early and late mutations 
associated with LAM resistance have also been reported, some of which are thought to act as 
compensatory mutations contributing to a recovery of replication efficiency in the face of  
antiviral resistance mutations (Bartholomeusz and Locarnini, 2006). LAM resistance 
mutations in the P gene of HBV have the capacity to also induce changes in the S gene which 
codes for HBsAg. This is because the S gene encoding for HBsAg is completely overlapped 
by the longer P gene (Torresi, 2002). Subsequently, some mutations in the P gene following 
nucleos(t)ide analogue therapy may result in structural changes in the HBsAg protein and a 
subsequent reduction in antigenicity (Torresi et al., 2002). HBsAg is the viral constituent in 
all current hepatitis B vaccines. It has been shown that recombinant HBsAgs bearing these 
changes behave as vaccine escape mutants (Carman et al., 1990).  
A recent investigation reported that the triple mutant, rtV173L/rtL180M/rtM204V, was more 
common in persons with HIV/HBV co-infection than in those with HBV infection only 
(Sheldon et al., 2007) indicating a potential selective advantage for this strain in 
immunosuppressed hosts, perhaps reflecting HBsAg epitope deletion. The triple mutant has 
been shown to produce a variant HBsAg which does not bind to vaccine-induced antibodies in 
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vitro and may promote vaccine failure (Torresi et al., 2002). The roll-out of ART gives ample 
opportunity for HIV therapy to induce drug resistant HBV and subsequent vaccine escape 
variants in co-infected patients. This is in addition to LAM-resistant variants that have already 
been identified in some therapy naive patients (Selabe et al., 2007). Use of TDF would 
circumvent the risk of HBV resistance that is associated with LAM use. TDF has a higher 
potency and genetic barrier compared to LAM but it unfortunately is not widely available in 
developing countries (Soriano et al., 2008). 
 
2.10. HBV vaccine in HIV era 
A study performed before the widespread availability of ART reported no transmission of 
HBV from mother to child in 598 babies although in fact only six children were born to 
known HBV-infected mothers, only one of whose serum contained HBeAg (Tsebe et al., 
2001). The findings provide encouraging data on the success of the HBV immunization 
program in the first five years of implementation even though HIV prevalence was not 
reported. It would appear that the child born to the HBeAg carrying mother was not tested for 
HBV DNA since the baby was negative for both anti-HBc and HBsAg. It would have been 
conclusive to test for HBV DNA because occult infection has been reported to occur in the 
absence of any serological markers (Lukhwareni et al., 2009; Hino et al., 2001).  
The rationale behind current immunization schedules is that the first dose of vaccine 
administered at six weeks will protect the infant by preventing subsequent horizontal HBV 
transmission in infancy which historically has been the usual route of infant transmission in 
SA. The fact that these babies remain at risk of perinatal mother to child transmission of HBV 
in the first 6 weeks of life is irrelevant if the HBV infected mother is of low HBV infectivity. 
It is also thought that maternal antibodies that are passively transferred will protect the infant 
during the period before it makes its own antibodies through active immunization (Ayoola, 
1988). However, HIV co-infection is likely to increase HBV replication in HIV/HBV co-
infected mothers and they will become more likely to transmit HBV perinatally, thereby 
altering the epidemiology of early infections (Burnett et al., 2005).   
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CHAPTER THREE 
 
3. Methods and materials 
3.1. Ethical approval 
The study was approved by the University of Stellenbosch‟s Health Research Ethics 
Committee (ethics clearance number N09/11/319) (Addendum A). Permission to use the 
patient serum was granted by the Western Cape Province Department of Health and South 
African National Department of Health (Addendum B). 
 
3.2. Study population and samples 
The samples tested in this study were drawn from a cohort of 9354 pregnant women from the 
Western Cape who were part of the 2008 South African National HIV and Syphilis Annual 
Antenatal Sentinel Survey. Their residual serum samples, following HIV and Syphilis testing 
were stored at -20 C in the Division of Virology at Tygerberg Hospital. From the 9354 
pregnant women, all HIV-infected women were identified and their samples were selected.  
Each sample from an HIV-infected subject was then matched to a single HIV negative sample 
according to race and age. This resulted in a total of 3099 women being selected for the study. 
 
3.3. Serology tests 
Serology tests were performed to detect markers that are associated with HBV diagnosis and 
prognosis. Serology tests were performed for HBsAg, HBeAg, anti-HBe and anti-HBc (total) 
and anti-HD (total). 
 
3.3.1. HBsAg testing 
All suitable (sufficient volume and non-heamolysed) samples from the cohort of 3099 
pregnant women were tested for HBsAg using the Abbott AxSYM (Abbott Diagnostics, 
Chicago, IL) according to the manufacturer‟s protocol. Four samples from the HIV-uninfected 
group and six from the HIV-infected group could not be tested because they were either 
haemolysed or had insufficient volume to be tested. As a result, 1546 HIV positive and 1543 
HIV positive samples were tested on the AxSYM.  
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The AxSYM is an automated immunoassay analyzer that uses the technology of micro 
particle enzyme immunoassays (MEIA) for qualitative detection of HBsAg in a patient‟s 
serum or plasma (Abbott AxSYM HBsAg (v2) kit insert). The principle of the AxSYM 
HBsAg (v2) assay is that there is direct binding of the HBsAg in the sample to anti-HBs 
coated micro particles and indirect detection of the HBsAg by biotinylated anti-HBs followed 
by anti-biotin-alkaline phosphatase conjugate (Abbott AxSYM HBsAg (v2) package insert). 
Substrate solution is then added and the fluorescent product formed is measured by the MEIA 
optical assembly. The reactions are carried out on a matrix cell instead of the conventional 
microwell plate. A negative or positive result for HBsAg is determined by comparing the rate 
of formation of fluorescent product from a patient‟s sample to the cut off rate of the index 
calibrator (Abbott AxSYM HBsAg (v2) package insert). To preserve volume for further tests, 
samples were diluted in 50% volume/volume (v/v) phosphate buffered saline: fetal bovine 
serum (PBS: FBS). All positive samples were re-tested on the Abbott AxSYM. This was done 
to rule out any false-positive results before neutralization was done. Quality of results from 
the AxSYM was ensured by testing calibrators and controls each day when the samples were 
tested.  
Dilution of samples was validated by testing two replicates of serial dilutions of an HBsAg 
standard from the National Institute of Biological Standards and Controls (NIBSC, 
Hertfordshire, UK) using the AxSYM and Murex HBsAg assays. The HBsAg standard was 
procured at a concentration of 33 IU/ml and was serially diluted in 50% PBS:FBS. The 
dilutions were tested on the AxSYM and the minimum detectable limit was determined to be 
0.04 IU/ml of HBsAg. In addition, known HBsAg positive samples were also diluted and 
tested. 
 
3.3.2. HBsAg confirmatory testing  
All samples that were repeatedly reactive for HBsAg on the AxSYM were confirmed using an 
in-house HBsAg neutralization assay. Sixty-one HIV positive and fifty HIV negative samples 
were subjected to the neutralization assay. The neutralization assay was performed using the 
Abbott Murex HBsAg Version 3 immunoassay kit (Murex Biotech, Kent, England) and anti-
HBs at a concentration of 10 IU/ml. Anti-HBs was provided by the Health Protection Agency 
(HPA) at Colindale, London. A sample volume of 50 µl was pipetted into each of two 
microcentrifuge tubes. To one tube, 50 µl of negative human plasma was added to the sample 
while 50 µl of anti-HBs positive plasma was added to the second microcentrifuge tube. The 
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tubes were then mixed by vortexing and left to incubate at 4 C overnight. HBsAg testing was 
performed after 16 hours using the Murex HBsAg kit according to the manufacturer‟s 
instructions. 
The principle of the HBV neutralization assay is that the anti-HBs antibodies added to the 
patient plasma/serum bind to and reduce the amount of HBsAg that will then bind to the anti-
HBs that is coated onto the microwell plates. In contrast, the negative human plasma does not 
contain any anti-HBs and therefore a greater amount of HBsAg should bind to the anti-HBs 
coated on the microwell plates during testing. The difference in the amount of surface antigen 
binding onto the microwell plates is measured spectrophotometrically in the immunoassay. If 
the sample is truly reactive for HBsAg, a decrease in colour intensity of at least 50% should 
be seen in the tube that was incubated with anti-HBs.  
The neutralisation assay is validated and is in use at the Health Protection Agency (Colindale, 
UK). Before being used in this study, the assay was verified for local conditions by 
performing an initial neutralization assay using an in-house positive control. Serial dilutions 
of the control were made using negative human plasma and these were then subjected to the 
neutralization test. The validation exercise showed that a sample with an HBsAg 
concentration of 0.04 IU/ml could be neutralized using the in-house neutralisation assay. 
 
3.3.2.1. Confirmatory HBsAg testing using the Abbott Murex HBsAg version 3 
immunoassay kit 
Each well is pre-coated with mouse monoclonal antibody to HBsAg that capture any HBsAg 
in a sample/control (Abbott Murex version 3 kit insert). A volume of 25 μl of sample diluent 
was added to each well of the microplate, followed by addition of 75 μl of the patient‟s 
sample that had been incubated with either negative human plasma or anti-HBs as mentioned 
before. The plate was covered with a lid and left to incubate for 60 minutes at 37°C.   
After the one hour incubation, 50 μl of conjugate was added to each well. The conjugate is 
composed of horseradish-peroxidase labelled goat antibody to HBsAg. The sides of the 
microplate were tapped gently for 10 seconds to release any air bubbles from the wells. The 
plates were covered with a lid again and incubated for 30 minutes at 37°C. At the end of the 
incubation time, the plate was washed five times on a Bio-Rad PW40 microplate washer (Bio-
Rad, Hercules, CA) using a wash fluid volume of 500 μl in each well. The wash step serves to 
remove excess or unbound HBsAg and conjugate from the well.  
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After washing was completed, the plate was inverted and tapped onto absorbent paper to 
remove any residual wash fluid. Substrate solution of 100 μl was immediately added to each 
well, the plate was covered with a lid and incubated for 30 minutes at 37°C to allow for 
colour development. The substrate solution contains hydrogen peroxide and 3,3‟,5,5‟-
tetramethylbenzidine (TMB). The TMB turns a purple colour when oxidised by the 
breakdown of hydrogen peroxide horseradish-peroxidase and antibody conjugate in the 
positive samples. Stop solution made of 50 μl of 1M sulphuric acid was then added to each 
well. Colour intensity for each well was measured on a microplate reader at 450 nm using 650 
nm as the reference wavelength on the dual wavelength Anthos HT3 Microtiter Plate Reader 
(Anthos Labtec Instruments GmbH, Salzburg, Austria). 
 The HBsAg reactivity in each well was then measured by comparing its absorbance to the 
cut-off value. The cut-off value for each run was calculated using the following formula that 
is provided by the kit manufacturer (Abbott Murex version 3 kit insert): Cut-off value = Mean 
of the Negative Control replicates + 0.05.  
 
3.3.3. HBeAg and anti-HBe testing 
Samples that were confirmed positive for HBsAg by the neutralization assay were tested for 
HBeAg and anti-HBe. Samples with insufficient volume after the neutralization assay were 
not tested for HBeAg and anti-HBe.  Testing for HBeAg and anti-HBe was performed using 
the DiaSorin ETI-EBK PLUS and ETI-AB-EBK PLUS immunoassay kits (DiaSorin S.pA, 
Salugia, Italy) respectively.  
 
3.3.3.1. HBeAg Testing 
The DiaSorin ETI-EBK PLUS assay is a direct, non-competitive assay and is based on the use 
of polystyrene microwells coated with mouse monoclonal antibodies to HBeAg (DiaSorin 
ETI-EBK PLUS kit insert). In the test, 50 µl of patient specimen/controls/calibrator was 
incubated with 50 µl of incubation buffer in antibody-coated microwells. The plates were 
sealed using a cardboard cover and left to incubate for two hours in a 37°C incubator. If 
HBeAg is present in a specimen or control, it binds to the anti-HBe antibody coated on the 
microwell. Excess sample was removed by a wash step on a Bio-Rad PW40 microplate 
washer, composed of five wash cycles using 400 µl of wash buffer.  
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A volume of 100 µl of enzyme tracer was then added to the microwells and allowed to 
incubate for one hour in a thermostatically-controlled 37°C incubator. The enzyme tracer 
contains antibodies to HBeAg conjugated to horseradish peroxidase and binds to any antigen-
antibody complexes present in the microwells. Excess enzyme tracer was removed by a wash 
step as previously described above. A 100 µl volume of tetramethylbenzidine/hydrogen 
peroxide (chromogen/substrate) solution was added to the microwells and allowed to incubate 
for 30 minutes at ambient temperature in the dark. Wells containing HBeAg bind to the 
antibody-enzyme conjugate whose enzyme then reduces the hydrogen peroxide, which then 
oxidizes the chromogen to a blue colour (DiaSorin ETI-EBK PLUS kit insert). The blue 
colour of oxidised TMB was converted to a more stable yellow by adding 100 μl of 0.4N 
aqueous sulphuric acid stop solution into all wells maintaining the order and rate in which 
chromogen/substrate had been added. The wells of samples without HBeAg remained 
colourless after addition of both the hydrogen peroxide/TMB solution and aqueous sulphuric 
acid (stop solution).  
Colour intensity of each well was measured spectrophotometrically using the Anthos HT3 
Microtiter Plate Reader at 450 nm, using 650 nm as the reference wavelength, within 15 
minutes of the addition of stop solution. The intensity of the yellow colour indicates carriage 
of e antigen in the patient‟s sample (DiaSorin ETI-EBK PLUS kit insert). Optical density 
values for study samples were compared to a cut-off value derived from the average optical 
density of the calibrator. The cut-off value was calculated by adding 0.060 to the average 
absorbance for the calibrator values after subtraction of the substrate blank absorbance value 
(DiaSorin ETI-EBK PLUS kit insert).  
 
3.3.3.2. Anti-HBe Testing 
The Diasorin ETI-AB-EBK PLUS assay is a competitive test based on the use of polystyrene 
microwells coated with mouse monoclonal antibodies to HBeAg (Diasorin ETI-AB-EBK 
PLUS kit insert). In the procedure, 50 μl of incubation buffer was added into all wells except 
for the blank well. Calibrator, negative and positive controls and samples at volume of 50 µl 
were pipetted into their respective wells followed by addition of 50 μl of neutralizing solution 
into all wells except for the blank well. The neutralization solution has, among other 
components, recombinant HBeAg (produced in transfected Escherichia coli bacteria) that 
provides the basis for the competitive assay (Diasorin ETI-AB-EBK PLUS kit insert). A 
cardboard sealer was then used to cover the plate in order to prevent evaporation followed by 
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gentle tapping of the reaction wells to release any air bubbles trapped in the liquid. The plates 
were incubated for two hours in a 37°C thermostatically-controlled incubator. Excess sample 
was removed by a wash step on the Bio-Rad PW40 microplate washer, composed of five 
wash cycles using 400 µl of wash buffer for each well.  
Following the wash step, 100 μl of working enzyme tracer solution was added into all wells 
except for the blank well. The enzyme tracer solution is a conjugate of antibody to HBeAg 
(mouse monoclonal) and horseradish peroxidase (HRP) and attaches to unbound HBeAg that 
is coated on the microwell plate (Diasorin ETI-AB-EBK PLUS kit insert). A cardboard sealer 
was applied onto the plate to prevent evaporation followed by gentle tapping of the reaction 
wells to release any air bubbles trapped in the liquid. The plate was incubated for one hour at 
37°C in a thermostatically-controlled incubator. After lapsing of the incubation period, the 
plates were washed again as previously described.  
Thereafter, 100 μl of tetramethylbenzidine/hydrogen peroxide chromogen/substrate solution 
was pipetted into all wells followed by incubation of the plate for 30 minutes at room 
temperature, away from direct or intense light. This was followed by addition of 100 μl stop 
solution into all wells. The absorbance of each well was measured using an Anthos HT3 
Microtiter Plate Reader at 450 nm, using 650 nm as the reference wavelength within 15 
minutes of adding the stop solution. The presence or absence of anti-HBe antibodies in each 
sample was determined by comparing the absorbance value of unknown samples to that of the 
cut-off value (Diasorin ETI-AB-EBK PLUS kit insert). The cut-off value was calculated using 
the manufacturer‟s provided formula which is determined by multiplying the mean 
absorbance of the calibrator values by 0.500 after subtraction of the substrate blank 
absorbance value (Diasorin ETI-AB-EBK PLUS kit insert). 
 
3.3.4. Anti-HBc (total) testing 
Following testing for HBsAg, a random sample of 161 HIV-positive and 154 HIV-negative 
samples were chosen from those that had tested HBsAg-negative on the AxSYM in order to 
test for total antibodies to HBV core antigen. This was done to determine the prevalence of 
exposure to HBV in HIV-infected and HIV-uninfected pregnant women. Testing for anti-HBc 
was performed using the Murex Anti-HBc (total) immunoassay kit (Murex Biotech, Kent, 
England), according to the instructions outlined by the manufacturer.  
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The Murex Anti-HBc (total) test is a competitive enzyme immunoassay for the detection of 
total antibodies against HBc antigen (Murex Anti-HBc (total) kit insert). The microwells of 
the kit are coated with recombinant HBcAg. Serum or plasma from patients and controls are 
incubated in the microwells and any anti-HBc present in the sample or control binds to the 
HBcAg immobilized on the well surface. Excess antibodies in the sample are removed by a 
wash step using wash buffer on a microplate washer. A second incubation is carried out 
during which the conjugate binds to any HBcAg on the well surface not blocked by anti-HBc 
from the test sample. The conjugate is composed of monoclonal anti-HBc combined with 
horseradish peroxidase. After washing to remove any unbound conjugate, a substrate solution 
containing 3,3‟,5,5‟-TMB and hydrogen peroxide is added to the wells. Wells which do not 
contain anti-HBc and therefore bind to conjugate will develop a blue/green colour which is 
converted to orange when the enzyme reaction is stopped with the addition of sulphuric acid 
(Murex Anti-HBc (total) kit insert). The intensity of colour is determined 
spectrophotometrically. The optical density is greatest in the absence of anti-HBc and falls 
with increasing concentrations of anti-HBc in the sample. 
 The microwell plate and the reagents used were allowed to equilibrate to room temperature 
for 30 minutes. Sample diluent of 50 μl was added to each well for every sample tested. This 
was followed by addition of 50 μl of patient sample or control to the corresponding well 
containing sample diluent. The microplate was then covered with a lid and incubated for 30 
minutes in a 37°C incubator. After the incubation period, the microplate was washed using 
500 μl of wash fluid for five cycles using a Bio-Rad microplate washer. Thereafter, 50 μl of 
conjugate was added to each well and the plate was allowed to incubate for 30 minutes at 
37°C in an incubator. The wash step was again repeated, followed by addition of 100 μl of 
substrate solution to each well. The plates were covered using a lid and incubated again 37°C 
in an incubator for 30 minutes.  Stop solution of 50 μl of 1M sulphuric acid was then added 
and the colour intensity of each well was measured using an Anthos HT3 microwell plate 
reader at 450 nm using 690 nm as the reference wavelength. The result for each sample was 
determined by comparing its optical density to the cut-off value. The value of the cut-off was 
calculated according to the formula provided by the manufacturer: the mean absorbance of the 
positive control was added to the mean absorbance of the negative control and the sum was 
divided by two (Murex Anti-HBc (total) kit insert). 
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3.3.5. Anti-HDV testing 
Samples were tested for HDV using the ETI-AB-DELTAK-2 (DiaSorin S.pA, Salugia, Italy), 
which is an ELISA kit for qualitative determination of total antibodies to hepatitis Delta 
antigen (total anti-HD) in serum or plasma samples. Similar to the test for antibodies to 
HBeAg, the ETI-AB-DELTAK-2 test kit is a competitive assay based on the use of 
polystyrene microwells coated with biotinylated anti-HD IgG (human) and recombinant 
HDAg (ETI-AB-DELTAK-2 kit insert). Manufacturer‟s protocol and recommendations were 
followed during testing for total antibodies to HDV. 
Briefly, 50 μl of sample/controls was added to the appropriate well. This was followed by 
addition of 100 μl of enzyme tracer into all wells except the blank well. The wells were sealed 
using cardboard seals supplied within the kit. The enzyme tracer contains amongst other 
components, human anti-HD Fab fragments conjugated to HRP which compete against anti-
HD contained in the sample/control for binding to the HDV antigen adsorbed onto the surface 
of the microwell plate (ETI-AB-DELTAK-2 kit insert). The plate was then incubated for three 
hours at 37°C. Thereafter, the plate was washed on a Bio-Rad microplate washer for five 
cycles using a wash fluid volume of 400 µl and allowing a soak period of 30 seconds between 
each cycle. The plate was blotted onto paper towel after the final wash cycle to remove excess 
fluid. A 100 µl volume of chromogen/substrate solution was then added to the plate which 
was then sealed again and left to incubate at room temperature (25°C) in the dark for 30 
minutes. The substrate/chromogen solution contains hydrogen peroxide and a 
tetramethylbenzidine derivative which is oxidised to a blue colour.  
After the 30 minutes incubation, 100 µl of blocking reagent was then added to the plates. The 
blocking reagent contains 1N sulphuric acid that stops further colour changes and changes the 
colour of the reaction from a blue colour to a stable yellow. The optical densities were then 
read at 450/630 nm using an Anthos HT3 automated plate reader. Cut-off value was 
calculated by using the formula-  
Cut-off value = 0.5 NC x¯  + 0.5 PC x¯  , where NC x¯   is the mean absorbance for the negative 
control and PC x¯   is the mean absorbance for the positive control (ETI-AB-DELTAK-2 kit 
insert).  
Samples with optical densities ≤ cut-off value were considered positive for anti-HD while 
samples with optical density values ≥ cut-off value were considered negative for anti-HD. 
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3.3.6. Quality control for serology assays 
Quality of results was ensured during testing by strictly following the manufacturers‟ 
protocols and instructions. Cut-off values were calculated and interpretation made following 
each individual kit protocol. Manufacturer kit controls and calibrators were used in every run. 
In addition, well characterized positive and negative in-house controls were incorporated in 
each run. On occasions where a result was in the “grey zone” such a sample was repeated in 
duplicate to get a definitive result. 
 
3.4. Molecular tests 
The molecular tests that were used included real-time PCR for quantitative detection of HBV 
DNA and nested PCR followed by direct sequencing using Sanger‟s chain termination 
method to determine HBV genotype as well as to detect the presence of drug-resistance or 
vaccine-escape mutations. Quantitative detection of HBV DNA was performed according to 
the protocol developed by Garson et al. with minor modifications (Garson et al, 2005). 
Genotyping and sequence analysis was done according to the protocols designed and in use at 
the Blood-Borne Virus Unit at the HPA Colindale (London, UK). 
 
3.4.1. HBV viral load testing 
3.4.1.1. DNA Extraction from serum 
HBV DNA was extracted, according to the manufacturer‟s protocol, from the serum samples 
using the QIAamp MinElute Virus Spin kit (QIAGEN, Hilden, Germany), a method that 
purifies nucleic acid  and removes inhibitors of PCR amplification.  
Before extraction, five microlitres of mCMV internal control at a concentration of 400 
copies/µl was added to each 200 µl of lysis buffer (Buffer AL). A 200 µl aliquot of serum was 
added to 25 µl QIAGEN protease solution in a sterile 1.5 ml microcentrifuge tube. Two-
hundred µl of the mCMV and buffer AL mixture was then added to the tube and mixed by 
pulse-vortexing for 15 seconds. The sample was then incubated at 56 C for 15 minutes in 
order to release a maximum yield of DNA from the degraded virions. The tube was then 
briefly centrifuged to remove liquid droplets from the cap. A volume of 250 µl of 99.99% 
ethanol (Sigma-Aldrich, St Louis, MO) was then added to the tube and the mixture was mixed 
by pulse-vortexing. The mixture was incubated for five minutes at room temperature. 
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The lysate was applied to a QIAamp MinElute column in a 2 ml collection tube and 
centrifuged at 8 000 rpm for one minute. This enabled the adsorption of the DNA onto the 
silica gel membrane of the spin column while allowing the rest of the liquid to pass through 
the column. The tube containing the filtrate was discarded and replaced with a clean 2 ml 
collection tube, and the QIAamp MinElute column was then washed with 500 µl Buffer AW1 
and centrifuged at 8 000 rpm for one minute. The wash step was repeated using 500 µl Buffer 
AW2 and centrifugation at 8 000 rpm for one minute in order to remove any residual 
contaminants. Again, the collection tube with the flow-through was discarded and replaced 
with a new collection tube and the column was subsequently washed using 500 µl of 99.99% 
ethanol. Since residual ethanol in the eluate may inhibit downstream applications, the spin 
column was centrifuged again at full speed (14 000 rpm) for three minutes in a clean 2 ml 
collection tube. To ensure complete removal of any residual ethanol, the columns were placed 
onto clean collection tubes and incubated on a dry heat block at 56 C for three minutes to 
evaporate the ethanol completely. The MinElute columns were then transferred to sterile, 
labelled 1.5 ml microcentrifuge tubes followed by application of 60 µl elution buffer (buffer 
AVE). The columns were allowed to incubate at room temperature for five minutes followed 
by centrifugation at 14 000 rpm for one minute to elute the DNA from the columns. The 
eluted HBV DNA was stored at -20 C. Known HBV positive samples and normal human 
plasma that was negative for HBV markers were used as positive and negative controls for the 
extraction procedure. 
 
3.4.1.2. Quantitative detection of HBV DNA using quantitative PCR 
Quantitative detection of HBV DNA was performed using real-time PCR on the Rotor Gene 
6000 real-time PCR machine (Corbett Sciences, Australia) according to the protocol 
developed by Garson et al. (Garson et al., 2005). Serial dilutions of a HBV standard (1 x 10
8 
IU/ml) were made in HBV DNA negative human plasma to give a range from 1 x 10
2
 – 1 x 
10
7
 IU/ml. The HBV standard was calibrated against the WHO HBV DNA standard (NIBSC, 
UK) with a viral load of 1 x 10
6
 IU/ml before use. Table 3.1 shows the primer and probe 
sequences that were used to amplify a highly conserved segment of the surface antigen gene 
as well the primer and probe sequences that were employed to amplify and detect the mCMV 
internal control. All primers and TaqMan probes were used at a concentration of 100 µM 
supplied by Applied Biosystems. A reaction volume of 25 µl was used. The PCR master mix 
reagents and their volumes are shown in the Table 3.2. 
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Table 3.1 Oligonucleotide primers used for quantitative detection of HBV DNA 
Primer/Probe Sequence 
HBV Primer 1 5'- GTGTCTGCGGCGTTTTATCA-3' 
HBV Primer 2 5'- GACAAACGGGCAACATACCTT-3' 
HBV Probe 5'FAM-CCTCTTCATCCTGCTGCTATGCCTCATC-TAMRA 
mCMV Primer 1 5‟-AACCCGGCAAGATTTCTAACG-3‟ 
mCMV Primer 2 5‟-ATTCTGTGGGTCTGCGACTCA -3‟ 
mCMV Probe 5‟-VIC-CTA GTC ATC GAC GGT GCA CAT CGG C-3'TAMRA 
 
The 2X QuantiTect QPCR mastermix was sourced from QIAgen (QIAGEN, GmbH, Hilden, 
Germany). Amplification and detection was carried out under the following cycling 
conditions: 1 cycle of 95 C for 15 minutes and 45 cycles of 95 C for 15 seconds and 60  for 
60 seconds. After completion of each run, results were analyzed using the Rotor-Gene 6000 
Series Software 1.7 (Corbett Life Sciences, Australia). For quality control of each run, 
negative and positive working controls were used. The positive control was supplied by 
NIBSC (NIBSC, UK). Nuclease-free water (QIAGEN, Hilden, Germany) was also used as a 
non-template control. 
Table 3.2 Reagent components of the quantitative HBV PCR reaction mix 
Reagent Concentration (pmol/μl) Volume/sample (μl) 
HBV primer 1 100 0.1 
HBV primer 2 100 0.1 
HBV probe 100 0.05 
mCMV primer 1 100 0.1 
mCMV primer 2 100 0.1 
mCMV probe 100 0.05 
2X QuantiTect QPCR mastermix N/A 12.5 
Nuclease-free water N/A 2 
Template  Variable 5 
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3.4.1.3. Determination of Limit of Quantification 
The lower limit of quantification was determined by performing serial dilutions of the NIBSC 
HBV DNA standard down to a level of 10 IU/ml. Five replicates of each serial dilution were 
then tested for HBV DNA in a single assay. The assay was performed twice to effectively 
give 10 replicates of each standard dilution. The lowest concentration of HBV DNA that 
could be detected in all 10 replicates was then considered as the limit of quantification. 
 
3.4.2. Direct Nucleotide Sequencing of HBV Surface Antigen Region 
All samples that had detectable HBV DNA during quantitative detection of HBV DNA were 
subjected to direct sequencing. The remnant extract from the quantitative detection assay was 
used. Pre-nested and nested PCR were performed using the primer sequences shown in the 
Table 3.3. 
Table 3.3 Oligonucleotide primers used for pre-nested PCR amplification of the HBV polymerase gene 
Primer Sequence Nucleotide position on HBV 
genome   
HBV Z 5' AGCCCTCAGGCTCAGGGCATA 3‟ 1179 - 1199 
HBV 3 5' CGTTGCCKDGCAACSGGGTAAAGG 3‟ 2478 - 2455 
HBV M 5‟ GACACA CTTTCCAATCAATNGG 3‟ 2306 - 2287 
HBV P 5‟ TCATCCTCAGGCCATGCAGT 3‟ 1292 - 1311 
Nucleotide positions of primers are numbered according to Pugh et al. (1986).  
 
3.4.2.1. First round PCR 
The PCR reaction master mix for each single  pre-nested reaction consisted of: 0.5 µl of 10 
mM  deoxynucleotide triphosphate (dNTP) mix (Bioline, London), 0.5 µl of the primer HBV 
3 at a concentration of 20 pmol/µl, 0.5 µl of primer HBV Z at concentration 20 pmol/µl, 2.5 
µl of 10XPCR buffer (Invitrogen, California), 0.75 µl of 50 mM magnesium chloride (MgCl2) 
(Invitrogen, California), 0.1 µl Thermus aquaticus (Taq) Polymerase (Invitrogen, California), 
5 µl of DNA template and 15.15 µl of nuclease-free water to make a total volume 25 µl. The 
following cycling conditions were used for pre-nested amplification: 95°C for 5 minutes, 34 
cycles of 94°C for 30 seconds, 55°C for 30 seconds 72°C for 60 seconds followed by a final 
extension cycle at 72°C for two minutes. 
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3.4.2.2. Second round PCR 
The PCR reaction master mix for each single nested reaction was composed of: 1 µl of 10 
mM dNTP mix (Bioline, London), 1 µl of primer HBV P at a concentration of 20 pmol/µl, 1 
µl of primer HBV M at concentration 20 pmol/µl, 5 µl of 10XPCR buffer (Invitrogen, 
California), 1.5 µl of 50 mM MgCl2 (Invitrogen, California), 0.2 µl Taq Polymerase 
(Invitrogen, California), 1 µl of DNA template and 39.3 µl of nuclease-free water to make a 
total volume 50 µl. The cycling conditions for the second round PCR were as follows: 
denaturation at 95°C for 5 minutes, 34 cycles of 94°C for 30 Seconds, 50°C for 30 Seconds, 
72°C for 60 seconds followed by a final extension at 72°C for 2 minutes. 
 
3.4.2.3. Nested PCR Product Visualization 
Following the second round PCR, product formation was visualized by gel electrophoresis. A 
2% gel was prepared by adding two grams of Promega Agarose to 100 ml of 1X tris-acetate-
ethylene diamine tetra acetic acid (TAE) buffer. 1X TAE buffer was prepared from a 50X 
stock solution that was prepared by mixing 57.1 ml of glacial acetic acid (Merck Chemicals, 
Germany), 242 g Tris base (Boehringer Mannheim, USA), 100 ml of 0.05M ethylene diamine 
tetra acetic acid (EDTA) and distilled water. The suspension was heated in a microwave oven 
on high power for five minutes to completely dissolve the agarose. To the gel, 10 µl of 5 
mg/ml of ethidium bromide was then added and mixed by swirling. The gel was cooled under 
running water before being poured into the electrophoretic tank and allowed to set for at least 
an hour at room temperature. Samples were wet-loaded using 6X Orange DNA loading dye 
(Fermentas, Lithuania). O‟GeneRuler 1 kilobase (kb) DNA ladder (Fermentas, Lithuania) was 
used as the molecular marker. Electrophoresis was then performed using a voltage of 90V for 
25 minutes. The gels were then viewed on the UVItec Prochemi (Cambridge, UK) image 
acquisition system. PCR products were seen by exposing the gel to ultraviolet light at 245 nm 
and collecting the data using the UVIProchemi image acquisition system. Afterwards, images 
were enhanced and edited using UVIband software (Cambridge, UK). A 1 kb fragment was 
expected on samples positive for PCR and an example of the pictures obtained is shown in 
Figure 3.1 
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Figure 3.1 Example of an electrophoresis migration pattern for positive samples on nested PCR of the 
HBV polymerase gene. The picture shows the expected 1kb bands that were seen in samples that could be 
amplified. 
 
3.4.2.4. PCR product clean-up 
Samples on which the expected band could be seen from the electrophoresis gel were then 
cleaned up using the Illustra GXF PCR DNA & Gel Band Purification Kit (GE Healthcare, 
Buckinghamshire, UK). The kit allows for purification and concentration of DNA from PCR 
mixtures using four essential steps of sample capture, sample binding, washing and elution. 
Sample capture is achieved by use of a sample capture buffer type 3 that denatures proteins 
from the PCR mixture. Binding of the DNA occurs when the sample is applied onto the 
Illustra GFX MicroSpin columns that have a silica membrane. Washing then follows using 
wash buffer type 1 which permits removal of salts and other contaminants from the membrane 
bound DNA. PCR primers also pass with the filtrate at this step and are not retained. This is 
followed by elution using the elution buffers provided within the kit or nuclease-free water. 
To purify and concentrate the amplified HBV DNA, GFX columns were placed onto labeled 
collection tubes for each sample. Five hundred µl of capture buffer type 3 was added directly 
to each column. An aliquot of 30 µl of PCR product was added to each column in its 
corresponding labeled tube followed by pipetting up and down four times. The tubes were 
then centrifuged for one minute at 13000 rpm. The filtrate was discarded and the GFX 
MicroSpin column was placed back inside the same collection tube. A 500 µl volume of wash 
buffer type 1 was pipetted to all tubes and these were centrifuged at 13000 rpm for one 
minute. The filtrate and collection tubes were discarded. Columns were placed onto new 
labeled microcentrifuge tubes. To release the purified DNA, 40 µl of nuclease free water was 
added to each column which was then left to incubate for one minute at room temperature. 
The tubes were then centrifuged at 13000 rpm for one minute to elute the sample DNA.  The 
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GFX MicroSpin columns were then discarded after centrifugation while the eluate was 
retained in the microcentrifuge tube. 
 
3.4.2.5. Measurement of Purified PCR product 
 To ensure that HBV DNA had not been lost during purification, its presence in the purified 
product was determined spectrophotometrically using the NanoDrop 1000 spectrophotometer 
(Thermofisher Scientific, USA). It utilises a patented sample retention technology that uses 
surface tension alone to hold the sample in place thereby eliminating the need for cuvettes and 
other sample containment devices and allows for rapid clean up. A 1 µl volume of the purified 
product was loaded onto the instrument and the concentration of DNA in each sample was 
determined, wiping with paper towel to clean the pedestals between samples. The results from 
the machine were printed out. 
 
3.4.2.6. Nucleotide Sequencing of HBV DNA from purified DNA 
All purified samples were sequenced for the surface antigen gene using the BigDye 
Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, California, USA). The kit 
performs fluorescence-based cycle sequencing reactions on single-stranded or double-
stranded DNA templates and on PCR fragments. The technology of the BigDye Terminator 
v3.1 Cycle Sequencing Kit is based on Sanger dideoxynucleotide chain termination DNA 
sequencing method, which uses PCR to incorporate fluorescent dye-labelled 
dideoxynucleotides into a population of oligonucleotides synthesised from a single strand of 
the target DNA. The kit contains all necessary reagents for the sequencing reaction in a 
reaction ready-to-use format and all that is needed is to provide the template and the template-
specific primers. The primers used to sequence the polymerase genes and their sequences are 
shown in Table 3.4. 
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Table 3.4 Primers used for sequencing of the polymerase region 
Primer Sequence Nucleotide positions on 
HBV genome 
HBV P 5' TCA TCC TCA GGC CAT GCA GT 1292 - 1311 
HBV M 5' GAC ACA CTT TCC AAT CAA TNG G 2306 - 2287 
HBV H             5‟ TAT CAA GGA ATT CTG CCC GTT TGT CCT 1767 - 1793 
HBV N             5‟ ACTGAGCCAGGAGAAACGGACTGAGGC 1991 - 1965 
 
For a sample to be sequenced, it had to contain a DNA concentration >10 ng/µl on the 
NanoDrop 1000. For samples that had a DNA concentration greater than 30 ng/µl, dilutions 
were made in an appropriate volume of nuclease-free water were performed to obtain a 
concentration between 15–20 ng/µl before sequencing. The sequencing PCR master mix for 
each reaction was made as shown in Table 3.5. 
 
Table 3.5 PCR Master Mix for HBV Sequencing Reaction 
 
Four reactions were set up according to the Table 3.5 for each sample corresponding to each 
primer that was used. Nine microlitres of the sequencing PCR master mix was pipetted onto 
well on a MicroAmp PCR plate.  The DNA template was then pipetted onto each 
predetermined well on the MicroAmp PCR plate before amplification on the ABI 9700 
thermocycler (Applied Biosystems, California). The following cycling conditions were used 
Reagents Concentration Quantity 
Terminator ready reaction mix - 1 µl 
ABI sequencing buffer - 3 µl 
Template Between 15-25ng 1 µl 
Primer 2.0 pmol/ul 1 µl 
Water - 4 µl 
Total volume  - 10 µl 
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for the sequencing PCR:  30 cycles of 96°C for 20 seconds, 50°C for 20 seconds and 60°C for 
four minutes, followed by an infinite hold at 4°C. The hold allowed for the MicroAmp PCR 
plate to be left on the machine overnight in instances where the next step could not be started 
immediately.  
 
3.4.2.7. Cleaning of sequencing PCR reactions  
Cleaning up of the sequencing PCR reactions was performed before the sequences were read 
on the genetic analyzer. This was done in order to remove unincorporated dye terminators 
prior to injection of samples on the genetic analyzer.  The BigDye XTerminator® Purification 
Kit (Applied Biosystems, California) was used to clean up the sequencing reactions. The kit is 
based on a DNA sequencing reaction purification method that removes unused BigDye® 
terminators and salts that would affect injection of sample and base calling if not removed.  
The BigDye® XTerminator purification kit consists of SAM solution and XTerminator 
solutions. To purify a single reaction well, the cleaning up solution was made by combining 
49.5 µl of SAM Solution with 11 µl of Xterminator suspension. The mixture was then 
vigorously vortexed for 10 seconds.  A volume of 55 µl of the premixed Xterminator reagent 
was added to each reaction on the MicroAmp Optical 96-well reaction plate. The MicroAmp 
Optical plate was sealed using a MicroAmp Optical sheet (Applied Biosystems, California) 
and placed on a Multi-microplate Genie microplate shaker (Scientific Industries, New York) 
where it was vortexed for 30 minutes at 2000 rpm. Afterwards, the MicroAmp plate was 
centrifuged for two minutes at 1000 x g to remove any droplets from the optical cover. The 
sealing optical sheet was removed and a septa mat was placed on the plate. The plate was then 
placed for sequence analysis on the ABI3130xl Genetic Analyzer (Applied Biosystems, 
California). 
 
3.4.3. Quality control for molecular assays 
Caution was observed to avoid contamination which leads to false positive results in PCR 
tests. Gloves were worn when performing all procedures and not transferred between the five 
dedicated rooms of the laboratory where different steps were performed. The rooms were 
dedicated for extraction, reagent preparation (clean area), gel electrophoresis and combined 
amplification and detection. Dedicated pipettes and filtered tips were also used and these were 
not moved between sections. Nuclease free water was used as a non-template control in all 
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assays. A working control from NIBSC was used for real-time PCR assays as mentioned 
previously. Working spaces were kept clean by thorough cleaning using 10% Virkon (Antec 
International, Suffolk, UK) followed by 70% ethanol. 
 
3.5. Sequencing data and phylogenetic analysis 
Sequence analysis and assembly was performed using Lasergene software, version 8 
(DNASTAR Inc, WI, USA). Lasergene is a suite of sequence handling software and 
databases. The suite contains different programmes that allow for sequence editing and map 
creation, contiguous assembly and multiple and pair wise alignments amongst other functions. 
Files were exported from the ABI3130xl Genetic Analyzer and imported into Lasergene 
software, v8. Consensus sequences were assembled from the four primer sequences and 
edited using SeqMan. The consensus sequences were exported from SeqMan. Genotypes and 
sub genotypes were obtained using online genotyping databases of Stanford University 
(http://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html), International Public 
Health Repository for Hepatitis B (www.hepseq.org/Public/Tool/annotator_tool.php) and the 
Max Planck Institute (http://www.geno2pheno.org).  
For detection of amino acid mutations in the polymerase and surface antigen regions, 
sequences were aligned with wild type sequences using ClustalV. The presence of an amino 
acid that is not known to be a natural polymorphism for that position was recorded as a 
mutation. The frequency of mutations on a particular codon was recorded. Phylogenetic trees 
were constructed using MegAlign. 
 
3.6. Statistical analysis 
Data was analyzed using Statistica software, version 10 (StatSoft, Oklahoma, USA). Fisher‟s 
exact test was used to analyze categorical (prevalence) data where there were small sample 
numbers. The Pearson chi-square test was used when sample numbers were sufficiently large. 
HBV DNA load values were log10 transformed. The Mann-Whitney test was used to compare 
median HBV viral loads between the HIV-negative and the HIV-positive groups. Medians 
were chosen to compare the viral load data as the values did not follow a normal distribution. 
Descriptive analyses are presented using median and 95% confidence intervals. Statistical 
significance was defined as two-tailed p<0.05. 
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CHAPTER FOUR 
 
4. Results 
4.1. Demographic data 
A total of 3089 samples were selected for the study. The demographic characteristics of the 
women from whom the samples were drawn are shown in Table 4.1. 
Table 4.1 Demographic data of patients sampled 
Characteristic HIV-uninfected HIV-infected 
Number of women selected 1546 1543 
Age 
Median 
Interquartile range 
Range 
 
26 years 
23 - 31 
12 - 44 
 
26 years 
23 - 31 
12 - 44 
Gravidity  
Median 
Interquartile range 
Range 
 
2 
1 - 3 
0-10 
 
2 
1 - 3 
0-10 
Parity    
Median 
Interquartile range 
Range 
 
1 
0 - 2 
0-7 
 
1 
0 - 2 
0-7 
Race  
African 
Mixed-race 
Unknown 
 
1297 (83.9%) 
203 (13.2%) 
46 (3.0%) 
 
1323 (85.7%) 
179 (11.6%) 
41 (2.7%) 
Education:≤ Grade 10 *747/1517 (49.2%) *901/1531 (58.9%) 
* denotes that some samples are not included in the analysis due to the data not being 
recorded in the original database. 
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4.2. Serology results 
Of the 3089 samples that were screened for HBsAg, the following results were obtained. Of 
the 1546 HIV-uninfected mothers, 50 samples were initially repeatedly reactive for HBsAg on 
the AxSYM giving an HBsAg prevalence of 3.2%. A neutralization test performed on the 
HIV-uninfected samples that had tested repeatedly positive for HBsAg confirmed true surface 
antigen carriage in only 44/50 samples resulting in an effective prevalence of 2.85%.  
Sixty out of a total of 1543 HIV-infected women tested positive on the initial HBsAg screen 
test performed on the Abbott AxSYM resulting in a prevalence of 3.9%. Of the 60 initially 
reactive samples, 53 had a positive neutralization test giving a final HBsAg prevalence of 
3.4%. These results are shown Table 4.2. 
 
Table 4.2 HBsAg testing results 
Serology Marker HIV-uninfected HIV-infected p-value 
Initial screen test on 
AxSYM 
50/1546 (3.2%) 60/1543 (3.9%)  
HBsAg Neutralization 44/50 (88%) 53/60 (88.3%)  
Final HBsAg rate 44/1546 (2.8%) 53/1543 (3.4%) 0.35 
 
Among the 203 HIV-uninfected women of mixed race, 5 (2.46%) had confirmed HBsAg 
carriage. Of the 179 HIV-infected women of mixed race, 5 (2.79%) had a positive HBsAg 
result confirmed by neutralization. 
Of the 1297 HIV-uninfected African women, 37 (2.85%) were confirmed positive by 
neutralization for HBsAg carriage while 48 of 1323 (3.63%) of HIV-infected African women 
were also positive for HBsAg.  
All the samples that were positive for HBsAg with enough remnant sample volume were 
tested for HBeAg and anti-HBe.  Four of the forty-four confirmed HBsAg positive samples 
from the HIV-uninfected group could not be tested for HBeAg and anti-HBe due to an 
insufficient sample volume. The serology results following HBeAg and anti-HBe testing are 
shown in Table 4.3. 
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Table 4.3 Results of HBeAg and anti-HBe testing of confirmed HBsAg positive samples 
HBV marker HIV-uninfected HIV-infected p-value 
HBeAg (%) 7/40 (17.5) 10/53 (18.9) 1.00 
Anti-HBe (%) 33/40 (82.5) 43/53 (81.1) 1.00 
 
Two of the HIV negative samples had optical density values that were just above the cut-off 
value while all ten HBeAg positive, HIV positive samples had optical densities that were 
beyond the upper limit of the plate reader on the HBeAg assay. One HIV negative sample was 
positive for both HBeAg and anti-HBe. However, the optical densities for both tests were low 
compared to all other samples. Also, one HIV negative sample was negative for both HBeAg 
and anti-HBe. 
From the HBsAg negative samples, 155 HIV negative and 161 HIV positive samples were 
randomly selected for total anti-HBc testing. One of the HIV negative samples had an 
insufficient sample volume for testing and is excluded from the results analysis. One of the 
HIV positive samples had insufficient volume for testing while one other HIV positive sample 
had an equivocal result and is excluded from the results analysis. The results obtained are 
depicted in tabular form in Table 4.4. 
 
Table 4.4 Total anti-HBc testing on HBsAg negative samples. 
Marker HIV-uninfected HIV-infected p value 
Number of samples 
tested for anti-HBc 
153 159  
Samples positive for 
anti-HBc, (%) 
42 (27.5)  68 (42.8)  0.006 
 
Total anti-HD was tested in 39 HBsAg positive, HIV negative samples. All the 39 samples 
were negative for anti-HD. Five of the HBsAg positive samples in the HIV-uninfected group 
were not tested for anti-HD because of an insufficient sample volume. 
Of 53 HBsAg positive and HIV positive samples, only 50 were tested for total anti-HD. The 
remaining three samples could not be tested due to an insufficient sample volume. All the 50 
samples that were tested for anti-HD were negative. 
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4.3. HBV DNA detection and quantification 
The lower limit of quantification for the assay on the Rotor Gene 6000 was determined to be 
20 IU/ml through repeat testing of standard serial dilutions. HBV DNA detection and 
quantification was attempted on all samples with confirmed HBsAg carriage as well as on 
samples that had tested positive for anti-HBc (total). A total of 44 HIV negative samples 
tested positive for HBsAg. Among the HBsAg-positive HIV-negative, 3/44 samples had 
insufficient volume for HBV DNA detection and quantification. As a result, only 41 of the 
HBsAg positive, HIV negative samples could be tested for HBV DNA using quantitative PCR 
(qPCR). All 53 HIV positive, HBsAg positive samples had enough volume for HBV DNA 
quantification. 
Of the HBsAg positive, HIV negative samples 32/41 had detectable DNA while the remaining 
9/41 had undetectable HBV DNA. Of the 32 samples with detectable DNA, 6 samples had 
HBV DNA below 20 IU/ml while 26 samples had levels ≥20 IU/ml. Of the HIV positive 
samples, 44/53 had detectable HBV DNA. Of the 44, there were 2 samples that had HBV 
DNA less than 20 IU/ml and the remaining 42 samples had HBV viral loads ≥20 IU/ml. The 
results obtained from the qPCR assays are shown in Table 4.5. 
Of all the HIV-positive, HBsAg positive samples, 17/53 (32.1%) had HBV viral loads >10
4 
IU/ml while 6/42 (13.4%) of all HIV-negative, HBsAg positive samples had viral loads >10
4 
IU/ml (Odds ratio = 2.83; 95% confidence interval: 1.00 -8.01; 
2
 : P = 0.04). 
HBV DNA was detected in all HBeAg positive samples from both groups. Of seven HIV-
uninfected women with positive HBeAg serology, five samples contained HBV DNA load 
greater than 4 log10 IU/ml with two of these having greater than 8 log10 IU/ml. Of the 10 HIV-
infected women with positive HBeAg serology, 90% had HBV DNA greater than 4 log10 
IU/ml with 50% of these having greater than 8 log10 IU/ml. 
Twenty-six of thirty-three (78.8%) of the samples from HIV-uninfected women with a 
positive anti-HBe result had detectable DNA. Only one sample had HBV DNA greater than 
10
4
 IU/ml with no sample having more than 10
8
 IU/ml. 
Thirty-four of forty-three (79.0%) of the HIV-infected women with positive anti-HBe had 
detectable HBV DNA. Eight of the thirty-four samples (23.5%) contained HBV DNA ≥104 
IU/ml. However, none of the eight samples had HBV DNA levels greater than 10
8
 IU/ml 
although three samples had ≥105 IU/ml with one of these three having ≥106 IU/ml of HBV 
DNA.  
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Table 4.5 HBV DNA detection and quantification in HBsAg positive samples 
Parameter HIV-uninfected HIV-infected p value 
HBsAg positive samples with 
detectable HBV DNA 
32/41 (78%) 44/53 (83%) 0.60 
Log10 HBV DNA of all 
HBsAg positive 
Median 
Interquartile range 
 
 
2.73 
2.08 - 3.85 
 
 
3.11 
2.27 - 5.05 
 
0.32 
Log10 HBV  DNA HBeAg 
positive only 
 
Median 
Interquartile range 
 
 
6.07 
3.10 - 8.21 
 
 
7.93 
5.44 - 8.62 
 
 
0.23 
Log10 HBV DNA anti-HBe 
positive only 
Median 
Interquartile range  
 
 
2.54 
2.00 - 3.10 
 
 
2.56 
2.00 - 4.20 
 
 
 
0.47 
 
The results of the log10 HBV DNA of all HBsAg positive samples according to HIV status are 
depicted in Figure 4.1 while the log10 HBV DNA viral load values for HBeAg positive 
samples only and anti-HBe positive samples for the two groups classified according to HIV 
status are shown in a combined graph in Figure 4.2.  
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Figure 4.1 Log10 HBV viral loads according to HIV status. The graph shows the medians (centre small box), 
25%-75% percentiles (outer box) and the minimum and maximum values (whiskers). 
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Figure 4.2 Log10 HBV Viral loads for HBeAg and anti-HBe positive samples. The graph shows the medians 
(centre small box), 25%-75% percentiles (outer box) and the minimum and maximum values (whiskers). A: 
Anti-HBe positive, HIV-uninfected, B: Anti-HBe positive, HIV-infected, C: HBeAg positive, HIV-uninfected, 
D: HBeAg positive, HIV-infected 
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4.4. Occult HBV testing 
The serologic results of HBsAg negative samples that were randomly selected for anti-HBc 
testing are shown in Table 4.7. The same table also has the results that were obtained on 
testing for HBV DNA using quantitative PCR. HBV DNA detection and quantification was 
performed only on samples that tested positive for anti-HBc. Seven of the forty-two HIV 
negative, anti-HBc positive samples had HBV DNA greater than 20 IU/ml while two had less 
than the quantification limit. Only five of the sixty-eight HIV positive, anti-HBc positive 
samples had HBV DNA greater than 20 IU/ml. The five remaining HIV positive samples with 
detectable DNA had HBV viral loads that were less than 20 IU/ml which was the 
quantification limit as stated previously. Statistical analyses are shown in table 4.7. 
 
Table 4.7 Serology and HBV DNA for occult infections 
Parameter HIV-uninfected HIV-infected 
Samples positive for total anti-HBc (%) 42/153 (27.5) 68/159 (42.8) 
Number of samples with detectable 
HBV DNA among anti-HBc positive 
samples 
8/42 (19.0%) 10/68 (14.7%) 
 
HBV DNA of anti-HBc positive (IU/ml) 
Median (IQR) 51(40-84) 59 (37-151) 
  
4.5. Sequencing results 
All samples with detectable DNA were subjected to a nested PCR on the polymerase gene 
region that also acts as the surface antigen coding region in a frame shifted manner. A nested 
PCR was performed on 54 HIV positive samples and 41 HIV negative samples. Of the 54 
HIV positive samples, a band was seen on 43 and these were subsequently sequenced while 
25/41 HIV negative samples had the 1 kb band on gel electrophoresis after the nested PCR. 
Forty-two of the HIV positive samples carried HBV genotype A1 while only one woman 
carried HBV genotype D, while twenty-one patients in the HIV-uninfected group had 
genotype A1 and the remaining four participants were infected with genotype D.  
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No drug-resistance associated or vaccine-escape mutations were detected in the HIV-infected 
group. The V173L mutation that is associated with resistance to LAM was detected in one 
patient among the HIV-uninfected group. The patient carried HBV genotype D. No vaccine-
escape mutations were detected in the HIV-uninfected patients. The amino acid sequences 
obtained were aligned with reference wild-type sequences to determine presence of other 
mutations that are as yet undefined on the surface antigen and polymerase regions. There was 
no particular clustering of mutations within the analyzed regions although some codons had 
frequencies that were higher than other positions. Most of the sequences obtained contained 
the S207N polymorphism which is characteristic of African HBV isolates. The frequency of 
the mutations that were obtained on different codons of the surface antigen is shown in Figure 
4.3. The frequency of mutations observed within codons 74 to 254 of the polymerase region 
are depicted in Figure 4.4. The highest number of mutations was observed on codons 105 and 
209 of the polymerase region in both HIV-uninfected and HIV-infected women. 
 
 
Figure 4.3 Frequency and location of amino acid substitutions within HBsAg, comparing HIV-infected 
and HIV-uninfected women. 
 
0
1
2
3
4
5
6
7
1
1
0
1
9
2
8
3
7
4
6
5
5
6
4
7
3
8
2
9
1
1
0
0
1
0
9
1
1
8
1
2
7
1
3
6
1
4
5
1
5
4
1
6
3
1
7
2
1
8
1
1
9
0
1
9
9
2
0
8
2
1
7
2
2
6
Fr
e
q
u
e
n
cy
 
sAg codon
HIV Negative
HIV Positive
Stellenbosch University  http://scholar.sun.ac.za
46 
 
 
The results shown in figure 4.3 illustrate that no classic vaccine escape mutations such as the 
G145R were detected this cohort. However, there were some mutations found within the a 
determinant (amino acid positions 124-147) of the major hydrophilic region (amino acid 
positions 99-169) to which vaccine-elicited antibodies are directed (Wu et al., 2010). Also 
there were no particular codons where mutations are restricted although there were more 
mutations within the HIV-infected group occurring at codons 45 and 204 of the surface 
antigen region. 
 
Figure 4.4 Frequency and location of mutations within the different codons of the polymerase region 
according to HIV status. 
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4.6. Characteristics of HBV genotypes 
 
Table 4.6 Characteristics of the HBV genotypes in isolated sequences 
Characteristic Genotype A Genotype D 
HBeAg positivity, (%) 14/63, (22) 3/5, (60) 
HBV DNA, log10 
Median, (IQR) 
 
2.8, (2.2-4.5) 
 
5.9, (2.6-6.1) 
 
 
 
4.7. Phylogenetic analysis 
The sequences where aligned with other reference sequences from other geographic regions 
including South Africa. The sequences clustered well with other African-derived sequences. 
There was close clustering with other previously characterized South African sequences. The 
phylogenetic tree obtained from alignment of the sequences from this study with other HBV 
sequences from Africa and elsewhere is shown in Figure 4.5. 
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Figure 4.5 Phylogenetic analyses of HBV genomes. The evolutionary history was inferred using the Neighbor-
Joining method (Saitou and Nei, 1987). The tree is drawn to scale, with branch lengths in the same units as those 
of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed 
using the Maximum Composite Likelihood method (Tamura, Nei, and Kumar, 2004). Evolutionary analyses 
were conducted in MEGA5 (Tamura et al., 2011). Sequences shown with a red triangle (genotype D) or red 
circle (genotype A) are from HIV-infected women from this study. Sequences shown with a black triangle 
(genotype A) or black circle (genotype D) are from HIV-uninfected women. 
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CHAPTER FIVE 
 
5. Discussion 
5.1. Serology results 
5.1.1. HBsAg prevalence rate 
An overall HBsAg carriage prevalence of 3.2% was obtained for the cohort (HIV-uninfected 
and HIV-infected women) in this study. When grouped according to HIV status, the 
prevalence of HBsAg was 2.8% in HIV-uninfected and 3.4% in HIV-infected women. There 
was no statistically significant difference in HBsAg carriage according to HIV status in this 
study although there was a slightly higher prevalence in the HIV-infected than in the HIV-
uninfected group.  
The overall prevalence obtained in this study is in agreement with results of previous studies 
conducted on pregnant women in South Africa. The prevalence rate of HBsAg in pregnant 
South African women, without regard to HIV status, has previously been estimated to range 
from 1.2% to 8.3% (Burnett et al., 2007; Guidozzi et al., 1993). Tsebe et al. also reported 
HBsAg prevalence of 3.2% in mothers of vaccinees (Tsebe et al., 2001). The HBsAg 
prevalence values of this study are also similar to more recent figures reported in Zimbabwe 
where the overall HBV prevalence rates were between 3.3% and 3.7% (Mavenyengwa et al., 
2010). However, the overall prevalence reported in this study is lower than has been 
previously found in other countries within SADC. An earlier study by Madzime et al. in 
Zimbabwe reported an HBsAg prevalence of 25% (Madzime et al., 1999) while Ahmed et al. 
reported 13% in Malawi (Ahmed et al., 1998). The reason for the difference in prevalence 
may be due to the fact that that there may be pockets of higher prevalence areas within South 
Africa and other African countries (Sinha and Kumar, 2010; Kew, 1996). Another reason for 
the difference of results between this study and others may be due to use of different methods 
and testing strategy. In this study, positive HBsAg results were confirmed by neutralization.  
The similarity in prevalence of HBV among HIV-uninfected and HIV-infected women is 
consistent with other studies on African women where no statistically significant differences 
in HBsAg carriage have been observed when results are grouped according to HIV status 
(Rouet et al., 2004; Oshitani et al., 1996). The prevalence of HBsAg in HIV-uninfected and 
HIV-infected pregnant women was previously reported to be between 4.8-6.2% and 5.8-9.5% 
respectively in earlier studies that were previously conducted in other provinces of South 
Africa (Burnett et al., 2007; Klugman et al., 1991). In a study on Zambian pregnant women, 
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Oshitani et al. observed HBsAg prevalence of 7.1% and 5.4% in HIV-infected and HIV-
uninfected women, respectively (Oshitani et al., 1996). In Malawi, the prevalence of HBsAg 
was 12% in HIV-uninfected women and 16% in HIV-infected women (Ahmed et al., 1998). 
The studies by Oshitani et al., 1996 and Burnett et al., 2007 were done on both rural and 
urban women and this may have contributed to the higher rates they reported. A recent South 
African study conducted on rural HIV-infected women from the Eastern Cape reported an 
HBsAg prevalence of 5.5% (Boyles and Cohen, 2011). However, it is not clear whether the 
prevalence of HBV differs between rural and urban areas. Earlier studies revealed significant 
differences in the HBsAg prevalence between rural and urban children (Abdool Karim et al, 
1988).  
Most studies on African populations do not seem to find different prevalence rates of HBsAg 
between HIV-infected and HIV-uninfected people and this has been attributed to the fact that 
most of the people who go on to contract HIV may have already been exposed to HBV in 
childhood because of the horizontal route of transmission that is prevalent in sub-Sahara 
Africa (Puoti et al., 2008; Burnett et al., 2005). This is in contrast to the developed countries 
where carriage of HBsAg carriage in HIV-infected cohorts may reach up to 10 times than is 
observed in rest of the population who are HIV-uninfected (Puoti et al., 2008; Kellerman et 
al., 2003). This is mainly attributed to the fact that transmission of HBV in the West peaks 
with onset of sexual activity and there HIV and HBV are contracted almost simultaneously 
(Puoti et al., 2008).  
 
5.1.2. HBeAg and anti-HBe prevalence 
The prevalence rate of HBeAg carriage in HBsAg positive pregnant women in this study was 
found to be 17.5% and 18.9% among HIV-uninfected and HIV-infected women, respectively. 
Prevalence rates that have been previously reported in sub-Saharan Africa vary widely and lie 
between 2-24% (Sinha and Kumar, 2010). HBeAg carriage in South Africa has previously 
been reported to be at 4.6% among HBsAg-positive pregnant women (Guidozzi et al., 1993). 
The study by Guidozzi et al. also reported a much lower prevalence of HBsAg compared to 
other South African studies. A limited number of studies have been conducted in South Africa 
to investigate the prevalence of HBeAg among HBsAg-positive pregnant women. However, 
in Zambia the prevalence of HBeAg was found to be 12.3% in HIV-uninfected women and 
25% in HIV-infected women who were positive for HBsAg (Oshitani et al., 1996). The 
HBeAg prevalence obtained in this study is however higher than the value of 3.3% that was 
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reported in neighboring Zimbabwe (Madzime et al., 1999). The only other study to report a 
high prevalence of HBeAg among HBsAg-positive patients in South Africa was performed on 
samples drawn from HIV-infected patients who were about to start therapy where 9/19 
patients were found to be HBeAg-positive (Firnhaber et al., 2008). It is apparent that the 
patients studied by Firnhaber et al. were immunocompromised due as evidenced by CD4 
counts <200 cells/µl. 
The HBeAg carriage rates reported from studies conducted on Southern African populations 
are similar to what has been reported in other parts of Africa. In Ivory Coast, the HBeAg 
carriage rates in patients positive for HBsAg have been reported as 22.2% among HIV-
infected women compared to 9.4% in HIV-uninfected pregnant mothers (Rouet et al., 2004). 
There is slightly higher but non-significant higher carriage of HBeAg in HBsAg positive 
HIV-infected pregnant women than in their HIV-uninfected counterparts. This may be 
attributed to the immunosuppression caused by co-infection with HIV (Oshitani et al., 1996). 
In this study, two of the seven women in the HIV-uninfected group who were positive for 
HBeAg had very low optical densities that suggested a rather weak positive result. One of the 
samples with a low HBeAg optical density was also positive for anti-HBe. The woman from 
whom the sample was drawn could potentially have been in the process of seroconverting 
from HBeAg to anti-HBe and this could have caused a double positive result because viral 
antigen and antibody titers are both low (Wang et al., 2011). The same explanation may also 
hold true for the one patient who had a double negative result (Wang et al., 2011).  
 
5.1.3. Total anti-HBc prevalence 
Total anti-HBc is a marker for previous exposure to HBV. The prevalence of anti-HBc in 
HIV-infected pregnant women was 42.8% which was statistically significantly higher than the 
27.0% observed in the HIV-uninfected group (p<0.05). These results suggest that a greater 
proportion of HIV-infected women are exposed to HBV compared to HIV-uninfected women. 
These findings are similar to what has been reported in other studies conducted in sub-
Saharan Africa. In South Africa, anti-HBc positivity in HBsAg-negative HIV-infected 
patients has previously been reported at 61.7% compared to 27.3% in HIV-uninfected women 
(Mphahlele et al., 2006). Another study conducted by Burnett et al. in South Africa reported 
anti-HBc carriage of 37.3% in HIV-infected pregnant women and 23.6% in the HIV-
uninfected group (Burnett et al., 2007). Barth et al. also reported an anti-HBc prevalence of 
28.1% among ART-naïve HIV-infected patients who were negative for HBsAg (Barth et al., 
2011). 
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It is difficult to comment on the clinical implications of anti-HBc results without information 
on the anti-HBs status of the women. Testing for anti-HBs would have provided more 
information on the HBV immune status of the women in the study. Anti-HBs are detected 
when an individual has recovered from HBV infection or when a person has successfully 
responded to HBV vaccine (Ganem and Prince, 2004). Presence of anti-HBs would also have 
provided better understanding on whether the women who tested positive for anti-HBc were 
true positives. Anti-HBs would also explain the great number of samples with no detectable 
HBV DNA since only 14.7% samples among the HIV-infected group and 21.4% in the HIV-
uninfected group had detectable DNA in their plasma. Alternatively, it would also have been 
verified if the women with positive anti-HBc results are part of the group of HIV-infected 
patients that have been widely described to have isolated anti-HBc positive serology 
(Mphahlele et al., 2006; Piroth et al., 2002; Owiredu et al., 2001; Grob et al., 2000;). 
 
5.1.4. Anti-HDV prevalence 
Infection with HDV only occurs in individuals who are carriers of HBV and whose serum has 
detectable HBsAg (Wedemeyer, 2010; Ojo et al., 1998). HDV leads to increased severity of 
liver disease in HBV carriers (Ojo et al., 1998). None of the samples tested positive for anti-
HDV in this study. This is similar to findings of an early study in the pre-HIV era on South 
African patients in which no delta antigen or antibodies to delta antigen were detected (Kew 
et al., 1984). More recently, no HDV carriage was found among a cohort of HIV-infected 
patients who were HBsAg-positive and about to start therapy (Firnhaber et al., 2008). A 
limited number of studies have been conducted to investigate the prevalence of HDV on 
African populations. Total anti-HDV antibodies were detected in 17.6% of chronic HBV 
carriers in Cameroon (Foupouapouognigni et al., 2011), 6.8% of asymptomatic carriers in 
Tunisia had positive HDV serology (Djebbi et al., 2009) and 6.5% of patients with chronic 
active liver disease in Nigeria (Ojo et al., 1998). No HDV was found amongst blood donors 
and university students in the Nigerian study (Ojo et al., 1998).  
Although no evidence of HDV was found in this study, it does not necessarily dismiss the 
presence of the delta antigen in South African patients. An investigation on patients with 
active chronic HBV liver disease may show different results. In Somalia, 50% of patients with 
histologically proven chronic liver disease who had HBsAg were found to have anti-HDV 
(Aceti et al., 1991). It also appears that HDV is more likely to be found in patients with 
chronic active HBV liver disease than in those that are healthy or asymptomatic.  
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5.2. Molecular results 
5.2.1. HBV DNA in HBsAg positive samples 
The results showed a trend towards higher replication in HIV/HBV co-infected pregnant 
women compared to HBV mono-infected women. However, the difference in median HBV 
viral loads in the two groups was not statistically significant. The more significant finding 
was the difference in the proportion of samples that contained HBV DNA greater than 10
4
 
IU/ml within the two groups. Among the HIV-positive, HBsAg positive samples, 32% had 
HBV viral loads >10
4
 IU/ml compared to only 14% among the HIV-negative, HBsAg positive 
samples (p<0.05). A cut-off value of 10
4
 IU/ml was considered as it has been shown to carry a 
relative risk of vertical transmission of 2.41 compared with lower viral load (Candotti et al., 
2007). These results clearly indicate that there is a higher proportion of HIV-infected pregnant 
women than HIV-uninfected pregnant women that have increased rates of HBV replication. 
Previous studies have shown that HIV/HBV co-infected patients have higher HBV replication 
rates than HBV mono-infected patients although none have investigated the viral loads in 
pregnant women particularly using a cut-off value that has a known risk of perinatal infection. 
 
5.2.2. HBV DNA in HBeAg positive only 
A trend toward higher median HBV DNA load values in the HIV-infected group than in the 
HIV-uninfected group was observed. When considering only samples that were positive for 
HBeAg, the HIV-infected group had an HBV DNA load median value of 7.93 log10 compared 
to a median value of 6.07 log10 obtained in the HIV-uninfected women. The differences 
observed between the medians were not statistically significant (p>0.05). However, the trend 
is in agreement with literature that states that there is higher replication of HBV in HIV/HBV 
co-infected patients than in HBV mono-infected patients (Hoffman and Thio 2007). It may 
also be argued that since the comparison is on HBeAg positive samples, the difference may 
not be statistically significant because highly replicating virus was being compared across 
both groups. The small numbers that were involved may also explain the reason for the 
findings being not statistically significant. Nevertheless, there were 5/10 (50%) samples from 
HBeAg positive HIV-infected women compared to 2/7 (28.6%) samples from HBeAg 
positive HIV-uninfected women that had HBV DNA ≥108 IU/ml. HBeAg positivity together 
with HBV DNA greater than 10
8
 copies/ml (~10
7
 IU/ml) has been associated with perinatal 
transmission of HBV (Wiseman et al., 2009). 
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5.2.3. HBV DNA in anti-HBe positive only 
Thirty two samples from pregnant women infected only with HBV contained detectable anti-
HBe with a median HBV DNA load of 2.54 log10 IU/ml while forty three samples from 
women infected with HIV and HBV contained detectable anti-HBe with a median HBV DNA 
load of 2.56 log10 IU/ml.  
As was observed among the samples with HBeAg, the HBV DNA load values in the HIV-
infected group were higher than in the HIV-uninfected pregnant women even though the 
difference did not reach statistical significance. More significant was the higher proportion of 
women infected with HIV who had HBV DNA values ≥104 IU/ml compared to the mono-
infected group. The high HBV DNA levels observed in some of the HBeAg negative, anti-
HBe positive samples suggest a need for vigilance to identify pregnant women who may 
potentially transmit HBV to their infants despite presence of anti-HBe which is associated 
with less infectivity.  
Earlier studies from Italy and Taiwan showed that the presence of anti-HBe was protective 
against vertical transmission of HBV (Gussetti et al., 1983; Stevens et al., 1979). However, 
presence of anti-HBe alone was later disproved to be protective against HBV transmission 
(Candotti, Danso, and Allain, 2007; Kazim et al., 2002). The stance that anti-HBe was 
protective against transmission probably arose from the fact that the technology to measure 
HBV DNA was not yet available. It is now known that the level of viraemia is the most 
important risk factor in determining risk of vertical transmission rather than the mere presence 
of anti-HBe (Candotti et al., 2007). Anti-HBe may be found together with high HBV viral 
load values in the serum of patients who have mutations in the basal core promoter gene of 
HBV where there is no synthesis and secretion of HBeAg. In Ghana where genotype E is 
predominant, it was shown that an HBV DNA load of >10
4
 IU/ml was associated with a 
relative risk of vertical transmission of 2.41 compared with lower viral load (Candotti et al., 
2007).  
 
5.2.4. HBV DNA in anti-HBc positive samples and occult infections 
Among the HIV negative HBsAg negative samples, 41/153 tested positive for anti-HBc 
(total) and 19% had detectable HBV DNA. This is in contrast to 68/159 samples from HIV-
infected, HBsAg negative women that tested positive for total anti-HBc of whom only 14.7% 
had detectable HBV DNA. 
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The rates of HBV viraemia amongst anti-HBc positive patients obtained in this study is 
different from what has been previously reported in South African patients. A previous study 
conducted on hospitalized patients at Dr. George Mukhari Hospital, revealed that 33.3% of 
HIV-infected patients with anti-HBc alone as the sole positive serology marker had HBV 
DNA in the absence of HBsAg while none of the HIV-uninfected patients with a similar 
serology pattern had detectable HBV DNA (Mphahlele et al., 2006). Also, another study 
performed at the same hospital revealed an occult HBV prevalence rate of 23% amongst HIV-
infected patients (Lukhwareni et al., 2009). The rates of occult HBV infection in HIV-infected 
patients reported in these studies are much higher than was obtained in this study. However, 
the study populations that were considered at Dr George Mukhari Hospital are different from 
the cohort investigated in this study.  The patients studied at Dr George Mukhari Hospital 
were either admitted in hospital or about to start antiretroviral therapy and may therefore have 
been more immunosuppressed than the HIV-infected women investigated in this study.  
It is assumed that pregnant HIV-infected women are likely to be more immunocompetent than 
symptomatic HIV-infected individuals though unpublished data from Tygerberg Hospital 
suggests that their CD4 counts are just as low as some AIDS patients in the general 
population. The changes in epidemiology of HBV in the setting of HIV co-infection are more 
apparent as HIV infection progresses to AIDS. 
 
5.2.5. HBV genotyping 
There are currently eight genotypes widely described for HBV ranging from genotype A to H 
(Kramvis et al., 2005). Only genotype A1 and genotype D3 isolates were obtained from the 
samples that were analyzed in this study. Genotypes were determined for 25 samples from the 
HIV-uninfected pregnant women and for 43 women from the HIV/HBV co-infected group. Of 
the 25 samples in the HBV mono-infected group, 21 samples belonged to genotype A1 while 
the remaining four belonged to HBV genotype D3. Forty two samples among the HIV/HBV 
co-infected group belonged to HBV genotype A1 while only one sample belonged to HBV 
genotype D3. These findings are consistent with literature on the genotypes found within 
South Africa. Genotype A1 has been isolated and described as being dominant in South 
Africa (Kramvis and Kew, 2007a; Kramvis and Kew, 2007b; Kimbi et al., 2004). Genotype D 
has also been isolated from infected HBV carriers in South Africa previously (Kramvis and 
Kew, 2007b). The genotype D samples isolated in this study were of sub-genotype D3 
consistent with the prior descriptions from South Africa.  
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Samples with genotype D had higher HBV DNA levels when compared to those with 
genotype A. The median HBV viral load for the genotype D isolates was 5.9 log10 IU/ml 
compared to 2.8 log10 IU/ml for samples with genotype A. The characteristics of the 
genotypes are in agreement with other published studies which showed that HBV carriers 
with genotype D have higher HBV viral loads when compared to patients with genotype A 
(Kramvis and Kew, 2005; Tanaka et al., 2004). Furthermore, 60% of samples belonging to 
genotype D were positive for HBeAg while 22% of the samples with genotype A1 isolates 
were HBeAg positive. This is also in agreement with previous studies that have shown that 
HBV carriers with genotype D are likely to be positive for HBeAg compared to those infected 
with genotype A1 (Tanaka et al., 2004). The observation that a higher proportion of genotype 
D samples were positive for HBeAg compared to genotype A samples also helps to explain 
the higher HBV DNA values observed.  
 The consensus sequences from this study were aligned with other sequences from South 
Africa deposited in GenBank and phylogenetic tress drawn from the alignment. There was 
phylogenetic clustering of the sequences from this study with other sequences that have been 
previously isolated from South African and other sub-Sahara African patients. This suggests 
that there may be a high degree of similarity in the surface antigen region of HBV genotypes 
A and D strains that are circulating within South Africa and sub-Saharan Africa at large. 
However, whole genome sequencing would allow validation of this hypothesis. 
 
5.2.6. Mutation analysis 
Amino acid alignments against wild type consensus genotype specific sequences were created 
for the HBsAg regions. These alignments were used to identify mutations within the antigen 
to which antibodies against the vaccine are directed. No vaccine-escape mutations were found 
in this study in either the HBV mono-infected group or the HIV/HBV co-infected group. This 
is encouraging data for the vaccination program as it suggests that wild type HBV strains are 
in circulation and thus the vaccine is likely to continue to be effective. The presence of 
vaccine-escape mutants would potentially render the current vaccine ineffective thereby 
exposing infants to infection despite immunisation. 
However, some amino acid changes were identified within the major antigenic region 
between codons 120 and 150 of the surface antigen in both the HIV-uninfected and HIV-
infected group. The frequency of these mutations was higher in the HIV-infected group than 
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in the HIV-uninfected group but it is difficult to ascertain whether this is due to HIV infection 
or because of the smaller number of HIV negative samples that could be analyzed.  
One sample from an HIV-uninfected woman with genotype D carried the valine to leucine 
change at codon 173 which forms part of the antiviral resistance profile for LAM (Benhamou 
et al., 1999). It cannot be established if the woman had exposure to LAM or if this was a 
spontaneous mutation. LAM resistance mutations in therapy naïve HBV-infected patients 
have previously been reported in South African and were significantly higher in HIV/HBV 
co-infected individuals (Selabe et al., 2007). 
 
5.3. Strengths and limitations of study 
The strengths of this cross-sectional study were that it had a simple study design, there was 
access to a large sample number and also that this was a collaborative research allowing use 
of techniques that have not been used in previous studies on pregnant women in Africa. The 
study also generates data on HBV viral loads in pregnant women which has not been reported 
before. 
The limitations of the study are as follows. No antiretroviral therapy or previous treatment 
information was provided for HIV-infected patients. Since this data is not collected during 
antenatal surveys, it could be possible that some of the HIV-infected patients may have had 
exposure to antiretroviral therapy which also controls HBV replication. This may have 
potentially contributed to lowering HBV DNA levels in the HIV-infected patients. Some 
samples with low HBsAg levels may have been missed by dilution although this is unlikely 
because dilutions were made on positive samples which were diluted by a factor of up to 
10 000 and HBsAg could still be detected. It therefore unlikely that true HBsAg positive 
samples will have been missed. Also, there were numerous freeze-thaws on samples which 
could lead to inaccurate results particularly in the serology tests, some of which are affected 
by the presence of fibrin. However, to reduce the effect of fibrin the samples were centrifuged 
prior to any testing. In addition, no data on immune status (CD4 counts) was available. 
Although data from different studies is conflicting on the effect of CD4 count on HBV 
disease progression, the study would have benefitted by knowing the immune status of the 
cohort that was investigated. Another limitation is that the study did not test for HBV DNA in 
all screened patients due to the cost. This may cause an underestimation of the actual 
prevalence of HBV within the population and it is possible that some samples that were 
positive for HBV DNA may have been missed due to the absence of screening serological 
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markers that were used. HBV DNA has been reported to occur in the absence of any 
serological markers (Lukhwareni et al., 2009; Hino et al., 2001). 
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CHAPTER SIX 
 
6. Conclusion 
This study has shown that there is a trend towards higher HBV replication in HIV-infected 
than in HIV-uninfected pregnant women. There was no difference in the proportion of women 
infected with HBV in both the HIV-uninfected and HIV-infected women. Of all HBsAg 
positive women, 24% had HBV DNA load greater than 10
4
 IU/ml and were at increased risk 
of transmitting HBV to their infants. More importantly, the study has shown that a higher 
proportion of HIV/HBV co-infected pregnant women have increased replication rates of HBV 
when compared to HBV mono-infected pregnant women. This study contributes to data that 
supports administering a birth dose of HB vaccine. Data from South Africa has shown that 
neonates born to HIV-infected mothers are significantly less likely to have protective levels of 
maternally-derived anti-HBs leaving them susceptible to horizontally transmitted infection 
(Jones et al., 2011). However, they do have robust immune responses to vaccine and it will 
therefore be safe to administer a birth dose of vaccine to these infants so that their can 
produce their own protective levels of anti-HBs. However, the efficacy of administering the 
birth dose to HIV-infected neonates will need to be evaluated because a separate study from 
South Africa reported that there was reduced detection and decreased levels of protective anti-
HBs to HBV vaccine (which leaves them susceptible to horizontal infection) in HIV-infected 
compared to HIV-infected children under the age of 2 years who were recruited at a peadiatric 
outpatient facility (Simani et al., 2009).  Administration of HBV vaccine at birth may be 
feasible for children born at health facilities but maybe be costly to administer in some places 
such as rural areas where there is a significant number of home-births (Kramvis and 
Clements, 2010). There will be a need to devise ways in which the vaccine can be 
administered to neonates born away from the health facilities and this may prove to be 
expensive, particularly when funds are scarcely available (Kramvis and Clements, 2010). 
The finding that 24% of all HBsAg positive women in this study had HBV viral loads greater 
than 10
4
 IU/ml also suggests a need for closer observation of both HIV-infected and HIV-
uninfected pregnant women who are HBV infected in order to provide the necessary care and 
intervention that will decrease their likelihood to vertically transmitting HBV to their infants. 
Necessary interventions may only be possible when there is a policy to screen pregnant 
women for HBV within the public health system under which most of these women will be 
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served. Currently, the HBsAg positive women in this cohort are unlikely to have been tested 
for HBV and would be at risk of transmitting the infection to their children.  
The results also point to the fact that there may be low levels of perinatal transmission 
currently occurring in the Western Cape when considering the number of women who had 
high HBV DNA levels and were HBeAg positive. Provision of high titre hepatitis B 
immunoglobulin would cater for children who will be born to infected mothers with high 
HBV DNA levels but the costs are prohibitive for developing countries like South Africa 
(Robson and Kirsch, 1991). Instead, LAM or TDF administration in the third trimester to 
women who are infected with HBV and at risk of transmitting the infection to their children 
presents a more feasible option and has been shown to be safe to use in pregnancy (Bzowej, 
2011; Kose et al., 2011; van Zonneveld et al., 2003). Currently, HIV-infected women with 
CD4 <350 cells/ml are receiving TDF and LAM as part of first line therapy. However, LAM 
or TDF are not widely available for HBV mono-infected patients in the public health sector 
under which most people are served. 
Further studies are needed to evaluate the extent of perinatal transmission especially 
considering the number of women that were found to contain HBeAg in this study. 
  
Stellenbosch University  http://scholar.sun.ac.za
61 
 
References 
Abdool Karim, S. S., Coovadia, H. M., Windsor, I. M., Thejpal, R., van den Ende, J., and 
Fouche, A. (1988). The prevalence and transmission of hepatitis B virus infection in urban, 
rural and institutionalized black children of Natal/KwaZulu, South Africa. Int J Epidemiol 
17(1), 168-73 
Aceti, A., Mohamed, O. M., Paparo, B. S., Mohamud, O. M., Quaranta, G., Maalin, K. A., 
and Sebastiani, A. (1991). High prevalence of anti-hepatitis delta virus antibody in chronic 
liver disease in Somalia. Trans R Soc Trop Med Hyg 85(4), 541-2. 
Ahmed, S. D., Cuevas, L. E., Brabin, B. J., Kazembe, P., Broadhead, R., Verhoeff, F. H., and 
Hart, C. A. (1998). Seroprevalence of hepatitis B and C and HIV in Malawian pregnant 
women. J Infect 37(3), 248-51. 
Audsley, J., Littlejohn, M., Yuen, L., Sasadeusz, J., Ayres, A., Desmond, C., Spelman, T., 
Lau, G., Matthews, G. V., Avihingsanon, A., Seaberg, E., Philp, F., Saulynas, M., 
Ruxrungtham, K., Dore, G. J., Locarnini, S. A., Thio, C. L., Lewin, S. R., and Revill, P. A. 
(2010). HBV mutations in untreated HIV-HBV co-infection using genomic length 
sequencing. Virology 405(2), 539-47. 
Ayoola, E. (1988). "Viral Hepatitis and Liver Disease." (A. Zuckerman, Ed.) Alan R Liss, 
New York. 
Barth, R. E., Huijgen, Q., Tempelman, H. A., Mudrikova, T., Wensing, A. M., and 
Hoepelman, A. I. (2011). Presence of occult HBV, but near absence of active HBV and HCV 
infections in people infected with HIV in rural South Africa. J Med Virol 83(6), 929-34. 
Bartholomeusz, A., and Locarnini, S. A. (2006). Antiviral drug resistance: clinical 
consequences and molecular aspects. Semin Liver Dis 26(2), 162-70. 
Boyles, T. H., and Cohen, K. (2011). The prevalence of hepatitis B infection in a rural South 
African HIV clinic. S Afr Med J 101(7), 470-1. 
Bruss, V. (2007). Hepatitis B virus morphogenesis. World J Gastroenterol 13(1), 65-73. 
Burnett, R. J., Francois, G., Kew, M. C., Leroux-Roels, G., Meheus, A., Hoosen, A. A., and 
Mphahlele, M. J. (2005). Hepatitis B virus and human immunodeficiency virus co-infection in 
sub-Saharan Africa: a call for further investigation. Liver Int 25(2), 201-13. 
Stellenbosch University  http://scholar.sun.ac.za
62 
 
Burnett, R. J., Ngobeni, J. M., Francois, G., Hoosen, A. A., Leroux-Roels, G., Meheus, A., 
and Mphahlele, M. J. (2007). Increased exposure to hepatitis B virus infection in HIV-
positive South African antenatal women. Int J STD AIDS 18(3), 152-6. 
Bzowej, N. H. (2011). Hepatitis B Therapy in Pregnancy. Curr Hepat Rep 9(4), 197-204. 
Candotti, D., Danso, K., and Allain, J. P. (2007). Maternofetal transmission of hepatitis B 
virus genotype E in Ghana, west Africa. J Gen Virol 88(Pt 10), 2686-95. 
Carman, W. F., Zanetti, A. R., Karayiannis, P., Waters, J., Manzillo, G., Tanzi, E., 
Zuckerman, A. J., and Thomas, H. C. (1990). Vaccine-induced escape mutant of hepatitis B 
virus. Lancet 336(8711), 325-9. 
Centers for Disease Control. Map 3-04. Prevalence of chronic infection with hepatitis B virus, 
2006. Accessed  in November 2011 from; 
http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-
travel/hepatitis-b.htm#2403  
Chen, H. L., Chang, M. H., Ni, Y. H., Hsu, H. Y., Lee, P. I., Lee, C. Y., and Chen, D. S. 
(1996). Seroepidemiology of hepatitis B virus infection in children: Ten years of mass 
vaccination in Taiwan. JAMA 276(11), 906-8. 
Chen, Y., Cheng, G., and Mahato, R. I. (2008). RNAi for treating hepatitis B viral infection. 
Pharm Res 25(1), 72-86. 
Chevaliez, S., and Pawlotsky, J.-M. (2008). Diagnosis and management of chronic viral 
hepatitis: Antigens, antibodies and viral genomes. Best Practice & Research Clinical 
Gastroenterology 22(6), 1031-1048. 
Colson, P., Borentain, P., Motte, A., Henry, M., Moal, V., Botta-Fridlund, D., Tamalet, C., 
and Gérolami, R. (2007). Clinical and virological significance of the co-existence of HBsAg 
and anti-HBs antibodies in hepatitis B chronic carriers. Virology 367(1), 30-40. 
Cooley, L., and Sasadeusz, J. (2003). Clinical and virological aspects of hepatitis B co-
infection in individuals infected with human immunodeficiency virus type-1. J Clin Virol 
26(2), 185-93. 
Daniels, D., Klevens, M., and Iqbal, K. (2010). 50th Interscience Conference on 
Antimicrobial Agents and Chemotherapy (ICAAC 2010), Boston. 
Stellenbosch University  http://scholar.sun.ac.za
63 
 
Davis, L. G., Weber, D. J., and Lemon, S. M. (1989). Horizontal transmission of hepatitis B 
virus. Lancet 1(8643), 889-93. 
Dény, P., and Zoulim, F. (2010). Hepatitis B virus: From diagnosis to treatment. Pathol Biol 
(Paris) 58(4), 245-253. 
Djebbi, A., Rebai, W. K., Bahri, O., Hogga, N., Sadraoui, A., and Triki, H. (2009). 
[Serological markers, viral RNA and genotype of hepatitis delta virus in HBs antigen positive 
Tunisian patients]. Pathol Biol (Paris) 57(7-8), 518-23. 
Firnhaber, C., Reyneke, A., Schulze, D., Malope, B., Maskew, M., MacPhail, P., Sanne, I., 
and Di Bisceglie, A. (2008). The prevalence of hepatitis B co-infection in a South African 
urban government HIV clinic. S Afr Med J 98(7), 541-4. 
Firnhaber, C., Viana, R., Reyneke, A., Schultze, D., Malope, B., Maskew, M., Di Bisceglie, 
A., MacPhail, P., Sanne, I., and Kew, M. (2009). Occult hepatitis B virus infection in patients 
with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South 
Africa. Int J Infect Dis 13(4), 488-92. 
Foupouapouognigni, Y., Noah, D. N., Sartre, M. T., and Njouom, R. (2011). High prevalence 
and predominance of hepatitis delta virus genotype 1 infection in Cameroon. J Clin Microbiol 
49(3), 1162-4. 
Francois, G., Kew, M., Van Damme, P., Mphahlele, M. J., and Meheus, A. (2001). Mutant 
hepatitis B viruses: a matter of academic interest only or a problem with far-reaching 
implications? Vaccine 19(28-29), 3799-815. 
Ganem, D., and Prince, A. M. (2004). Hepatitis B virus infection--natural history and clinical 
consequences. N Engl J Med 350(11), 1118-29. 
Garson, J. A., Grant, P. R., Ayliffe, U., Ferns, R. B., and Tedder, R. S. (2005). Real-time PCR 
quantitation of hepatitis B virus DNA using automated sample preparation and murine 
cytomegalovirus internal control. J Virol Methods 126(1-2), 207-13. 
Gilbert, N., Corden, S., Ijaz, S., Grant, P. R., Tedder, R. S., and Boxall, E. H. (2002). 
Comparison of commercial assays for the quantification of HBV DNA load in health care 
workers: calibration differences. J Virol Methods 100(1-2), 37-47. 
Gish, R. G. (2008). Diagnosis of chronic hepatitis B and the implications of viral variants and 
mutations. Am J Med 121(12 Suppl), S12-21. 
Stellenbosch University  http://scholar.sun.ac.za
64 
 
Grob, P., Jilg, W., Bornhak, H., Gerken, G., Gerlich, W., Gunther, S., Hess, G., Hudig, H., 
Kitchen, A., Margolis, H., Michel, G., Trepo, C., Will, H., Zanetti, A., and Mushahwar, I. 
(2000). Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 62(4), 450-5. 
Grob, P. J. (1998). Hepatitis B: virus, pathogenesis and treatment. Vaccine 16 Suppl, S11-6. 
Guidozzi, F., Schoub, B. D., Johnson, S., and Song, E. (1993). Should pregnant urban south 
African women be screened for hepatitis B? S Afr Med J 83(2), 103-5. 
Gussetti, N., Pornaro, E., Largajolli, G., and D'Elia, R. (1983). Vertical transmission of HBV 
from mothers HBsAg positive, anti-HBe positive. Dev Biol Stand 54, 405-8. 
Harrison, T. J., Mahy, B. W. J., and Regenmortel, M. H. V. v. (2008a). Hepadnaviruses: 
General Features. In "Encyclopedia of Virology", pp. 335-342. Academic Press, Oxford. 
Harrison, T. J., Mahy, B. W. J., and Regenmortel, M. H. V. v. (2008b). Hepatitis B Virus: 
Molecular Biology. In "Encyclopedia of Virology", pp. 360-367. Academic Press, Oxford. 
Health Protection Agency. Recommended protocol for HBV genotyping and for antiviral 
resistance analysis. 
http://www.hpa.org.uk/ProductsServices/InfectiousDiseases/LaboratoriesAndReferenceFacilit
ies/VirusReferenceDepartment/BloodBorneVirusesUnit. Accessed August 2010.  
Heathcote, E. J. (2008). Demography and presentation of chronic hepatitis B virus infection. 
Am J Med 121(12 Suppl), S3-11. 
Herrero Martinez, E. (2001). Hepatitis B and hepatitis C co-infection in patients with HIV. 
Rev Med Virol 11(4), 253-70. 
Hino, K., Katoh, Y., Vardas, E., Sim, J., Okita, K., and Carman, W. F. (2001). The effect of 
introduction of universal childhood hepatitis B immunization in South Africa on the 
prevalence of serologically negative hepatitis B virus infection and the selection of immune 
escape variants. Vaccine 19(28-29), 3912-8. 
Hoffmann, C. J., and Thio, C. L. (2007). Clinical implications of HIV and hepatitis B co-
infection in Asia and Africa. Lancet Infect Dis 7(6), 402-9. 
Hou, J., Liu, Z., and Gu, F. (2005). Epidemiology and Prevention of Hepatitis B Virus 
Infection. Int J Med Sci 2(1), 50-57. 
Stellenbosch University  http://scholar.sun.ac.za
65 
 
Horvath, J., and Raffanti, S. P. (1994). Clinical aspects of the interactions between human 
immunodeficiency virus and the hepatotropic viruses. Clin Infect Dis 18(3), 339-47. 
 
Howard, C. R. (1986). The biology of hepadnaviruses. J Gen Virol 67 ( Pt 7), 1215-35. 
Hudson, C. P. (1990). How AIDS forces reappraisal of hepatitis B virus control in sub-
Saharan Africa. Lancet 336(8727), 1364-7. 
Jayaraman, S., Chalabi, Z., Perel, P., Guerriero, C., and Roberts, I. (2010). The risk of 
transfusion-transmitted infections in sub-Saharan Africa. Transfusion 50(2), 433-442. 
Jones, C. E., Naidoo, S., De Beer, C., Esser, M., Kampmann, B., and Hesseling, A. C. (2011). 
Maternal HIV infection and antibody responses against vaccine-preventable diseases in 
uninfected infants. JAMA 305(6), 576-84. 
Kao, J. H., and Chen, D. S. (2002). Global control of hepatitis B virus infection. Lancet Infect 
Dis 2(7), 395-403. 
Kazim, S. N., Wakil, S. M., Khan, L. A., Hasnain, S. E., and Sarin, S. K. (2002). Vertical 
transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 359(9316), 
1488-9. 
Kellerman, S. E., Hanson, D. L., McNaghten, A. D., and Fleming, P. L. (2003). Prevalence of 
chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency 
virus-infected subjects. J Infect Dis 188(4), 571-7. 
Kew, M. C. (1996). Progress towards the comprehensive control of hepatitis B in Africa: a 
view from South Africa. Gut 38 Suppl 2, S31-6. 
Kew, M. C. (2008). Hepatitis B virus infection: the burden of disease in South Africa. South 
Afr. J. Epidemiol Infect 23(1), 4-8. 
Kew, M. C. (2010). Hepatocellular carcinoma in African Blacks: Recent progress in etiology 
and pathogenesis. World J Hepatol 2(2), 65-73. 
Kew, M. C., Dusheiko, G. M., Hadziyannis, S. J., and Patterson, A. (1984). Does delta 
infection play a part in the pathogenesis of hepatitis B virus related hepatocellular carcinoma? 
Br Med J (Clin Res Ed) 288(6432), 1727. 
Stellenbosch University  http://scholar.sun.ac.za
66 
 
Kiire, C. F. (1996). The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a 
view from tropical and subtropical Africa. Gut 38 Suppl 2, S5-12. 
Kimbi, G. C., Kramvis, A., and Kew, M. C. (2004). Distinctive sequence characteristics of 
subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol 85(Pt 5), 1211-
20. 
Klugman, K. P., Patel, J., Sischy, A., and McIntyre, J. A. (1991). Serological markers of 
sexually transmitted diseases associated with HIV-1 infection in pregnant black women. S Afr 
Med J 80(5), 243-4. 
Kose, S., Turken, M., Devrim, I., and Taner, C. (2011). Efficacy and safety of lamivudine 
treatment in late pregnancy with high HBV DNA: a perspective for mother and infants. J 
Infect Dev Ctries 5(4), 303-6. 
Kramvis, A., Kew, M., and Francois, G. (2005). Hepatitis B virus genotypes. Vaccine 23(19), 
2409-23. 
Kramvis, A., and Kew, M. C. (2005). Relationship of genotypes of hepatitis B virus to 
mutations, disease progression and response to antiviral therapy. J Viral Hepat 12(5), 456-64. 
Kramvis, A., and Kew, M. C. (2007a). Epidemiology of hepatitis B virus in Africa, its 
genotypes and clinical associations of genotypes. Hepatol Res 37(s1), S9-S19. 
Kramvis, A., and Kew, M. C. (2007b). Molecular characterization of subgenotype A1 
(subgroup Aa) of hepatitis B virus. Hepatology Research 37(SUPPL. 1). 
Kramvis, A., and Clements, C. J. (2010). Implementing a birth dose of hepatitis B vaccine for 
home deliveries in Africa--too soon? Vaccine 28(39), 6408-10. 
Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current 
and emerging prevention and control measures. J Viral Hepat 11(2), 97-107. 
Lin, C. L., and Kao, J. H. (2011). The clinical implications of hepatitis B virus genotype: 
Recent advances. Journal of Gastroenterology and Hepatology 26(SUPPL. 1), 123-130. 
Lukhwareni, A., Burnett, R. J., Selabe, S. G., Mzileni, M. O., and Mphahlele, M. J. (2009). 
Increased detection of HBV DNA in HBsAg-positive and HBsAg-negative South African 
HIV/AIDS patients enrolling for highly active antiretroviral therapy at a Tertiary Hospital. J 
Med Virol 81(3), 406-12. 
Stellenbosch University  http://scholar.sun.ac.za
67 
 
Lüsebrink, J., Schildgen, V., Schildgen, O. (2009). Chapter 5: HBV - Virology. 2009 ed. In 
"HEPATOLOGY A clinical textbook" (Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer.). 
Madzime, S., Adem, M., Mahomed, K., Woelk, G. B., Mudzamiri, S., and Williams, M. A. 
(1999). Hepatitis B virus infection among pregnant women delivering at Harare Maternity 
Hospital, Harare Zimbabwe, 1996 to 1997. Cent Afr J Med 45(8), 195-8. 
Maruyama, T., Iino, S., Koike, K., Yasuda, K., and Milich, D. R. (1993). Serology of acute 
exacerbation in chronic hepatitis B virus infection. Gastroenterology 105(4), 1141-51. 
Mavenyengwa, R. T., Moyo, S. R., and Nordbø, S. A. (2010). Streptococcus agalactiae 
colonization and correlation with HIV-1 and HBV seroprevalence in pregnant women from 
Zimbabwe. European Journal of Obstetrics & Gynecology and Reproductive Biology 150(1), 
34-38. 
Mphahlele, J. M., and Francois, G. (2008). Joining forces against infectious diseases in sub-
Saharan Africa. South Afr J Epidemiol Infect 23(1), 2-3. 
Mphahlele, M. J. (2008). Impact of HIV co-infection on hepatitis B prevention and control: a 
view from sub-Saharan Africa. South Afr J Epidemiol Infect 23(1), 14-18. 
Mphahlele, M. J., Lukhwareni, A., Burnett, R. J., Moropeng, L. M., and Ngobeni, J. M. 
(2006). High risk of occult hepatitis B virus infection in HIV-positive patients from South 
Africa. J Clin Virol 35(1), 14-20. 
Mulrooney-Cousins, P. M., and Michalak, T. I. (2007). Persistent occult hepatitis B virus 
infection: experimental findings and clinical implications. World J Gastroenterol 13(43), 
5682-6. 
Ohkawa, K., Takehara, T., Kato, M., Deguchi, M., Kagita, M., Hikita, H., Sasakawa, A., 
Kohga, K., Uemura, A., Sakamori, R., Yamaguchi, S., Miyagi, T., Ishida, H., Tatsumi, T., and 
Hayashi, N. (2008). Supportive role played by precore and preS2 genomic changes in the 
establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 198(8), 1150-8. 
Ojo, O. S., Akonai, A. K., Thursz, M., Ndububa, D. A., Durosinmi, M. A., Adeodu, O. O., 
Fatusi, O. A., and Goldin, R. D. (1998). Hepatitis D virus antigen in HBsAg positive chronic 
liver disease in Nigeria. East Afr Med J 75(6), 329-31. 
Stellenbosch University  http://scholar.sun.ac.za
68 
 
Olinger, C. M., Jutavijittum, P., Hubschen, J. M., Yousukh, A., Samountry, B., Thammavong, 
T., Toriyama, K., and Muller, C. P. (2008). Possible new hepatitis B virus genotype, southeast 
Asia. Emerg Infect Dis 14(11), 1777-80. 
Oshitani, H., Kasolo, F. C., Mpabalwani, M., Mizuta, K., Luo, N. P., Suzuki, H., and 
Numazaki, Y. (1996). Prevalence of hepatitis B antigens in human immunodeficiency virus 
type 1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 
90(3), 235-6. 
Owiredu, W. K., Kramvis, A., and Kew, M. C. (2001). Hepatitis B virus DNA in serum of 
healthy black African adults positive for hepatitis B surface antibody alone: possible 
association with recombination between genotypes A and D. J Med Virol 64(4), 441-54. 
Pawlotsky, J. M. (2006). Virology of hepatitis B and C viruses and antiviral targets. J Hepatol 
44(1 Suppl), S10-3. 
Piroth, L., Binquet, C., Vergne, M., Minello, A., Livry, C., Bour, J. B., Buisson, M., Duong, 
M., Grappin, M., Portier, H., and Chavanet, P. (2002). The evolution of hepatitis B virus 
serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen 
in HIV infected patients. J Hepatol 36(5), 681-6. 
Prozesky, O. W., Szmuness, W., Stevens, C. E., Kew, M. C., Harley, E. J., Hoyland, J. A., 
Scholtz, J. E., Mitchell, A. D., Shabangu, A., Kunene, E., and et al. (1983). Baseline 
epidemiological studies for a hepatitis B vaccine trial in Kangwane. S Afr Med J 64(23), 891-
3. 
Pugh, J. C., Weber, C., Houston, H., and Murray, K. (1986). Expression of the X gene of 
hepatitis B virus. J Med Virol 20(3), 229-46. 
Pungpapong, S., Kim, W. R., and Poterucha, J. J. (2007). Natural history of hepatitis B virus 
infection: an update for clinicians. Mayo Clin Proc 82(8), 967-75. 
Puoti, M., Airoldi, M., Bruno, R., Zanini, B., Spinetti, A., Pezzoli, C., Patroni, A., Castelli, F., 
Sacchi, P., Filice, G., and Carosi, G. (2002). Hepatitis B virus co-infection in human 
immunodeficiency virus-infected subjects. AIDS Rev 4(1), 27-35. 
Puoti, M., Manno, D., Nasta, P., and Carosi, G. (2008). Hepatitis B Virus and HIV 
Coinfection in Low-Income Countries: Unmet Needs. Clinical Infectious Diseases 46(3), 367-
369. 
Stellenbosch University  http://scholar.sun.ac.za
69 
 
Quasdorff, M., and Protzer, U. (2010). Control of hepatitis B virus at the level of 
transcription. J Viral Hepat 17(8), 527-36. 
Robson, S. C., and Kirsch, R. E. (1991). National strategy for viral hepatitis: 
recommendations and guidelines for management in South Africa. S Afr Med J 80(7), 347-56. 
Rouet, F., Chaix, M. L., Inwoley, A., Msellati, P., Viho, I., Combe, P., Leroy, V., Dabis, F., 
and Rouzioux, C. (2004). HBV and HCV prevalence and viraemia in HIV-positive and HIV-
negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 
74(1), 34-40. 
Saito, T., Shinzawa, H., Uchida, T., Kawamata, O., Honma, S., Watanabe, H., Shao, L., Saito, 
K., Togashi, H., and Takahashi, T. (1999). Quantitative DNA analysis of low-level hepatitis B 
viremia in two patients with serologically negative chronic hepatitis B. J Med Virol 58(4), 
325-31. 
Saitou, N., and Nei, M. (1987). The neighbor-joining method: a new method for 
reconstructing phylogenetic trees. Mol Biol Evol 4(4), 406-25. 
Sangare, L., Sombie, R., Combassere, A. W., Kouanda, A., Kania, D., Zerbo, O., and 
Lankoande, J. (2009). [Antenatal transmission of hepatitis B virus in an area of HIV moderate 
prevalence, Burkina Faso]. Bull Soc Pathol Exot 102(4), 226-9. 
Selabe, S. G., Lukhwareni, A., Song, E., Leeuw, Y. G., Burnett, R. J., and Mphahlele, M. J. 
(2007). Mutations associated with lamivudine-resistance in therapy-naive hepatitis B virus 
(HBV) infected patients with and without HIV co-infection: implications for antiretroviral 
therapy in HBV and HIV co-infected South African patients. J Med Virol 79(11), 1650-4. 
Sheldon, J., Ramos, B., Garcia-Samaniego, J., Rios, P., Bartholomeusz, A., Romero, M., 
Locarnini, S., Zoulim, F., and Soriano, V. (2007). Selection of hepatitis B virus (HBV) 
vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing 
antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 46(3), 279-82. 
Shepard, C. W., Simard, E. P., Finelli, L., Fiore, A. E., and Bell, B. P. (2006). Hepatitis B 
virus infection: epidemiology and vaccination. Epidemiol Rev 28, 112-25. 
Simani, O. E., Leroux-Roels, G., Francois, G., Burnett, R. J., Meheus, A., and Mphahlele, M. 
J. (2009). Reduced detection and levels of protective antibodies to hepatitis B vaccine in 
Stellenbosch University  http://scholar.sun.ac.za
70 
 
under 2-year-old HIV positive South African children at a paediatric outpatient clinic. 
Vaccine 27(1), 146-51. 
Simonsen, L., Kane, A., Lloyd, J., Zaffran, M., and Kane, M. (1999). Unsafe injections in the 
developing world and transmission of bloodborne pathogens: a review. Bull World Health 
Organ 77(10), 789-800. 
Sinha, S., and Kumar, M. (2010). Pregnancy and chronic hepatitis B virus infection. Hepatol 
Res 40(1), 31-48. 
Soriano, V., Puoti, M., Peters, M., Benhamou, Y., Sulkowski, M., Zoulim, F., Mauss, S., and 
Rockstroh, J. (2008). Care of HIV patients with chronic hepatitis B: updated 
recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22(12), 1399-
1410. 
Soriano, V., Vispo, E., Labarga, P., Medrano, J., and Barreiro, P. (2010). Viral hepatitis and 
HIV co-infection. Antiviral Res 85(1), 303-15. 
Stevens, C. E., Neurath, R. A., Beasley, R. P., and Szmuness, W. (1979). HBeAg and anti-
HBe detection by radioimmunoassay: correlation with vertical transmission of hepatitis B 
virus in Taiwan. J Med Virol 3(3), 237-41. 
Tamura, K., Nei, M., and Kumar, S. (2004). Prospects for inferring very large phylogenies by 
using the neighbor-joining method. Proc Natl Acad Sci U S A 101(30), 11030-5. 
Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011). MEGA5: 
molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, 
and maximum parsimony methods. Mol Biol Evol 28(10), 2731-9. 
Tanaka, Y., Hasegawa, I., Kato, T., Orito, E., Hirashima, N., Acharya, S. K., Gish, R. G., 
Kramvis, A., Kew, M. C., Yoshihara, N., Shrestha, S. M., Khan, M., Miyakawa, Y., and 
Mizokami, M. (2004). A case-control study for differences among hepatitis B virus infections 
of genotypes A (subtypes Aa and Ae) and D. Hepatology 40(3), 747-55. 
Tatematsu, K., Tanaka, Y., Kurbanov, F., Sugauchi, F., Mano, S., Maeshiro, T., Nakayoshi, 
T., Wakuta, M., Miyakawa, Y., and Mizokami, M. (2009). A genetic variant of hepatitis B 
virus divergent from known human and ape genotypes isolated from a Japanese patient and 
provisionally assigned to new genotype J. J Virol 83(20), 10538-47. 
Stellenbosch University  http://scholar.sun.ac.za
71 
 
Thimme, R., Spangenberg, H. C., and Blum, H. E. (2005). Hepatitis B or hepatitis C and 
human immunodeficiency virus infection. J Hepatol 42 Suppl(1), S37-44. 
Torresi, J. (2002). The virological and clinical significance of mutations in the overlapping 
envelope and polymerase genes of hepatitis B virus. J Clin Virol 25(2), 97-106. 
Torresi, J., Earnest-Silveira, L., Deliyannis, G., Edgtton, K., Zhuang, H., Locarnini, S. A., 
Fyfe, J., Sozzi, T., and Jackson, D. C. (2002). Reduced antigenicity of the hepatitis B virus 
HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase 
gene that are selected by lamivudine therapy. Virology 293(2), 305-13. 
Tran, T. T. (2009). Management of hepatitis B in pregnancy: weighing the options. Cleve Clin 
J Med 76 Suppl 3, S25-9. 
Trevino, A., Soriano, V., Madejon, A., Rodriguez, C., Barros, C., Botecchia, M., Tuma, P., 
Del Romero, J., and De Mendoza, C. (2009). Short communication: Transmission of hepatitis 
B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. AIDS 
Research and Human Retroviruses 25(12), 1273-1276. 
Tsebe, K. V., Burnett, R. J., Hlungwani, N. P., Sibara, M. M., Venter, P. A., and Mphahlele, 
M. J. (2001). The first five years of universal hepatitis B vaccination in South Africa: 
evidence for elimination of HBsAg carriage in under 5-year-olds. Vaccine 19(28-29), 3919-
26. 
Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization 
(WHO). (2009). AIDS epidemic update 2009. 
 http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf 
van Zonneveld, M., van Nunen, A. B., Niesters, H. G., de Man, R. A., Schalm, S. W., and 
Janssen, H. L. (2003). Lamivudine treatment during pregnancy to prevent perinatal 
transmission of hepatitis B virus infection. J Viral Hepat 10(4), 294-7. 
Vardas, E., Mathai, M., Blaauw, D., McAnerney, J., Coppin, A., and Sim, J. (1999). 
Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med 
Virol 58(2), 111-5. 
Wang, J., Zhou, B., Lai, Q., Wang, Y., Shen, G., Wang, Z., Chen, J., and Hou, J. (2011). 
Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E 
antigen and antibody detection. J Viral Hepat 18(9), 646-52. 
Stellenbosch University  http://scholar.sun.ac.za
72 
 
Wasmuth, J.C. (2009). Chapter 2: Hepatitis B - Epidemiology, transmission and natural 
history. 2009 ed. In "HEPATOLOGY A clinical textbook" (Mauss, Berg, Rockstroh, 
Sarrazin, Wedemeyer). 
Wedemeyer, H. (2010). Hepatitis D revival. Liver International 31, 140-144. 
Wedermeyer, H. (2009). Chapter 7: Prophylaxis and vaccination of viral hepatitis. 2009 ed. In 
"HEPATOLOGY A clinical textbook" (Mauss, Berg, Rockstroh, Sarrazin, Wedemeyer). 
World Health Organization (2008). Fact sheet N°204 Revised August 2008. Accessed June 
2010 from; http://www.who.int/mediacentre/factsheets/fs204/en/print.html 
Wiseman, E., Fraser, M. A., Holden, S., Glass, A., Kidson, B. L., Heron, L. G., Maley, M. 
W., Ayres, A., Locarnini, S. A., and Levy, M. T. (2009). Perinatal transmission of hepatitis B 
virus: an Australian experience. Med J Aust 190(9), 489-92. 
Yu, H., Yuan, Q., Ge, S. X., Wang, H. Y., Zhang, Y. L., Chen, Q. R., Zhang, J., Chen, P. J., 
and Xia, N. S. (2010). Molecular and phylogenetic analyses suggest an additional hepatitis B 
virus genotype "I". PLoS One 5(2), e9297. 
  
Stellenbosch University  http://scholar.sun.ac.za
73 
 
Addendum A 
Ethical Approval – Health Ethics Research Committee 
 
Stellenbosch University  http://scholar.sun.ac.za
74 
 
 
  
Stellenbosch University  http://scholar.sun.ac.za
75 
 
Addendum B 
Ethical approval – Department of Health 
 
 
Stellenbosch University  http://scholar.sun.ac.za
